FROM THE GUEST EDITOR’S DESK

- EVALUATION OF ADULTS FOR FAMILIAL MYELOID MALIGNANCY PREDISPOSITION: EYES ON THE PRIZE OF PREVENTION
  Presented by: Jane Churpek, MD, MS
  UW Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin

PLAN TO ATTEND

ASH 2020: MDS FOUNDATION BREAKFAST SYMPOSIUM
December 4, 2020
San Diego, California

16TH INTERNATIONAL CONGRESS ON MYELODYSPLASTIC SYNDROMES
May 5–8, 2021
Toronto, Canada

IN THIS ISSUE

FROM THE GUEST EDITOR’S DESK 2
MEETING HIGHLIGHTS & ANNOUNCEMENTS 7
ASH 2020: MDS Breakfast Symposium 7
2nd Latin American MDSF Symposium 8
RESEARCH
International Working Group for Prognosis in MDS 9
MDS/MPN International Working Group 11
MDS FOUNDATION LEADERSHIP 13
MDS AWARENESS WALKS 14
MDS LITERATURE HIGHLIGHTS 15
UPDATES IN MDS 18
CORD BLOOD REGISTRY 19
MDS CENTERS OF EXCELLENCE 20
MDS FOUNDATION MEMBERSHIP 25
PATIENTS AND CAREGIVERS LIVING WITH MDS FORUMS 27
IN THE NEWS 28
TESTIMONIALS 31
OUR PATIENT STORIES 32
OUR CAREGIVER STORIES 38
AML CORNER 40
MPN CORNER 45
CONTRIBUTIONS TO THE FOUNDATION
  Gifts 50
  Memorial Donations 55
  Living Endowments 56

www.mds-foundation.org
EYES ON THE PRIZE OF PREVENTION

EVALUATION OF ADULTS FOR FAMILIAL MYELOID MALIGNANCY PREDISPOSITION: EYES ON THE PRIZE OF PREVENTION

JANE E. CHURPEK, MD, MS
UW Carbone Cancer Center,
School of Medicine and Public Health
Madison, Wisconsin

INTRODUCTION

Advancements in the field of familial myeloid malignancy predisposition in only a few years have been remarkable, taking us from rarely thinking about a hereditary contribution to our adult patients’ histories to now a growing number of mainstream clinical guidelines including and encouraging thought of these disorders in every case.1-3 Each year, the list of genes and disorders helping to explain the hereditary contribution to another subset of patients with myeloid malignancies grows,4,5 and studies of the biological pathways disrupted are shedding light into early events in myelodysplastic syndromes (MDS) initiation. These are all FANTASTIC developments. However, we are still a long way off from maximizing the potential of familial myeloid malignancy predisposition assessment for MDS patients worldwide and using knowledge gained toward the ultimate goal of preventing MDS/acute myeloid leukemia (AML). Let us reflect on progress and critical needs for future progress by working through an illustrative case.

CASE EXAMPLE

A 63-year-old man presents for hematology evaluation due to a three-month history of neutropenia (absolute neutrophil count 900,000/microliter) and thrombocytopenia (90,000/microliter) found incidentally on laboratories done at a preventative care visit. He feels in his usual state of health and denies recent infections, bleeding, or fatigue. A bone marrow biopsy and aspirate reveal a hypocellular marrow with prominent erythroid dysplasia and 4% blasts. Karyotype is 46,XY[20].

PROGRESS IN THE PROCESS

At face value, this case is straightforward. He now has a new diagnosis of MDS with single lineage dysplasia and can be managed accordingly. However, if his hematologist has incorporated universal family history screening into his/her clinical practice as a growing number of hematologists are, 1 out of every 7 to 9 similar adult myeloid malignancy patients will report at least one close relative with a hematologic malignancy. (unpublished data,6,7) In this particular patient’s case, he was especially worried about his blood count values because he had two siblings who died of myeloid malignancies: one of MDS and the other of AML (Figure 1A).

Does this new information impact his diagnosis? YES. Based on the family history alone, unless there is a major known shared exposure risk factor, this family warrants a clinical diagnosis of a familial MDS/AML syndrome. Communicating this information to the pathologist who made the MDS diagnosis will change the bone marrow diagnosis line to add the following descriptor from Table 17 in the World Health Organization myeloid neoplasm classification guidelines: myeloid neoplasm with germline mutation.1 The next challenge is to find the gene that fills in that blank.

For low-grade MDS diagnoses, the pathologist may also need to reevaluate the bone marrow with this new information to ask whether an overt MDS diagnosis is warranted. Single or even multilineage dysplasia can be observed at baseline in individuals with known familial myeloid malignancy syndromes due to germline gene defect-related abnormalities in hematopoiesis. This makes an MDS diagnosis based on dysplasia alone especially challenging and has created calls for hereditary syndrome-specific criteria for MDS diagnosis.8,9

Patterns and Probability

Studies of germline mutation prevalence in unselected “sporadic” MDS/AML cases are beginning to define how common hereditary myeloid malignancy predisposition syndromes are in adults. For example, a recent French series found causative germline mutations in DDX41 in 2.4% of 1385 adults with MDS/AML.10 Early data from the BEAT AML Master trial, which is attempting to collect a skin biopsy on all newly diagnosed AML patients, also found DDX41 mutations in 2.8% of 176 patients age 60 or older.11 The National MDS Natural History Study (NCT 02775383) is collecting germline samples on its planned 3500 newly diagnosed patients, which will hopefully better define prevalence estimates specifically in MDS cases.12,13 Optimal germline samples, comprehensive gene lists, expert rare variant interpretation, as well as follow-up functional testing and family-based segregation studies of rare variants will be critical to maximizing information gained from these large scale studies.

Case series of families with each myeloid malignancy predisposition syndrome from different settings around the world are also helping to refine patterns suggestive of one syndrome versus others. Cytopenias at initial MDS/AML diagnosis with a bone marrow featuring hypocellularity, prominent erythroid dysplasia, and a normal karyotype are all classical findings in familial MDS/AML due to DDX41 mutation.10,14,15 For DDX41,
series from the United States, Japan, Taiwan, and France have demonstrated different recurrent mutation sites within the DDX41 gene by country that could contribute to gene by ethnic background specific features. In contrast, de novo AML with M1 or M2 morphology and double CEBPA mutations without preceding blood count abnormalities would have suggested familial AML due to CEBPA mutation. MDS featuring dysplastic megakaryocytes, increased reticulin fibrosis, and often monosomy 7 is common in GATA2 deficiency syndrome.

While initially intimidating, recognizing these patterns can be just like a good resident morning report. “Did Mr. X have a history of lymphedema? NO. How about pulmonary fibrosis? NO....” In this process, yeses are more informative than noes because all of these disorders are incompletely penetrant for each feature. This means that a patient can still have familial platelet disorder with myeloid malignancy predisposition (FPD) even if they do not have the characteristic preceding history of thrombocytopenia or bleeding tendency. Similarly, they can have GATA2 deficiency syndrome without a clinical history of lymphedema or warts. Arming oneself with tables from the literature, rote memorization, or one’s own mnemonics (GATA2 deficiency syndrome has CLAW: CMML/MDS, Lymphedema, Atypical infection, Warts) can aid in pattern recognition. Recognizing syndrome-specific features can even yield a legitimate clinical diagnosis. In fact, expert clinicians are right 91% of the time in clinically diagnosing a specific inherited bone marrow failure syndrome later confirmed molecularly through genetic testing. With practice, you can do it too!

Going through this process for the patient above (Figure 1A-D), first, consider possible inheritance patterns. Keep in mind the size of the family and age of both affected and unaffected individuals, paying attention to whether the unaffected individuals have lived long enough to develop features. For our patient, his children are too young to know what may happen to them over time. Three affected siblings could result from an autosomal dominant pattern with incomplete penetrance, meaning the parent who also carries the mutation did not develop a myeloid malignancy in their lifetime. This would be the most common pattern for adult-onset familial myeloid malignancy syndromes, but autosomal recessive or other patterns are also possible.

Next, note the median age at MDS/AML presentation (Figure 1B). Our patient’s family’s median is 63 years, fitting best with the median age of onset of 63 years observed in familial MDS/AML due to DDX41 mutation versus the 19, 25, and 33 years observed in GATA2 deficiency, familial AML due to CEBPA mutation, and FPD, respectively. Presenting and historical blood counts, bone marrow cellularity, lineage-specific dysplasia(s), karyotype, and acquired gene mutations can also be helpful as noted in the patterns described above. In his case, the prominent erythroid dysplasia, hypocellular marrow, and normal karyotype are all classical findings in familial MDS/AML due to DDX41 mutation. A review of systems asking key targeted questions such as the presence of anomalies, pulmonary fibrosis, and an infectious disease history rounds out this evaluation.

Functional Testing and Genetics

For those lucky enough to have ready access to germline and acquired multi-gene tests, one may consider just skipping the memorizing and quizzing to wait for the genetic tests to provide the answer. Well, unfortunately, it’s not so straightforward. Outside of a small number of recurrent mutations affecting multiple families, the germline mutations identified in the majority of families with most of these syndromes will be unique or “private” to a single family. Thus, if clinical laboratories have never seen this variant before, all of the work that was put in characterizing the clinical phenotype above can really pay off—making a variant that would otherwise end up in the purgatory of genetics, a so-called variant of uncertain significance (“VUS”), instead be classified as a clinically useful likely pathogenic or pathogenic variant that can be acted upon. Functional tests, where available, such as chromosome breakage
testing for Fanconi anemia, can also cinch a clinical diagnosis or aid in interpretation of genetic variants identified. Thus, the sum of careful clinical phenotyping, genetic testing, and functional tests is greater than any individual part in making a diagnosis (Figure 2). Ongoing efforts to improve rare variant classification in familial myeloid malignancy predisposition genes take advantage of this fact, incorporating syndrome-specific clinical features and functional tests to better differentiate the benign from clinically actionable variants and hopefully minimize VUSs.25

If an acquired mutation panel is performed along with germline testing, the combined mutational pattern can further suggest a likely diagnosis. For example, if our patient had had a myeloid malignancy focused panel that included DDX41, we would have identified both his germline DDX41 mutation (p.D140fs) as well as an acquired DDX41 mutation (p.R525H), a recurrent mutation that is commonly acquired on the previously normal allele at the time of myeloid malignancy in this syndrome.26 Because several of the hereditary myeloid malignancy predisposition genes are frequently mutated somatically in MDS, such as RUNX1 and TP53,27 these genes are already on most acquired mutation panels used for MDS diagnostic and prognostic purposes. Some centers are further adapting acquired mutation panels to specifically include additional hereditary myeloid malignancy predisposition genes that are not yet prognostic or predictive for MDS therapeutic purposes but instead to screen for a hereditary etiology. Although most of the mutations found in an MDS sample will be acquired, DDX41 is different because the majority of the mutations found in this gene are germline.10,28 Thus, consenting patients to MDS “acquired” panels, especially if adapted for screening the germline, should acknowledge this intention. Overall, paired germline and acquired multi-gene testing along with clinical phenotyping and functional testing have the greatest chance of providing a molecular diagnosis to inform management for the patient and identify those at risk in the family for counseling and risk management.

CRITICAL NEEDS TO KEEP MOMENTUM GOING

Adult hematology is experiencing a major paradigm shift going from the assumption that familial predisposition is exceedingly rare (Figure 3) to growing recognition by both patients as well as clinicians at the time of diagnosis that the family history is important. A second paradigm shift is also occurring. This one involves recognition that paired germline and acquired genetic assessment at diagnosis can impact the interpretation of blood and bone marrow findings, the official World Health Organization classification, and management of MDS patients. Critical needs to keep the momentum going and maximize potential benefit of familial myeloid malignancy predisposition assessment for clinical care and science are outlined below.

Education

First and foremost, investment in hereditary hematology-focused educational opportunities for diverse disciplines, such as genetic counselors, medical geneticists, benign and malignant hematologists,
primary care providers, nurses, and advanced practitioners, is crucial to helping more patients with MDS or who are at risk for MDS be recognized. With more practitioners comfortable with the spectrum of hematologic diagnoses and vocabulary and aware that it is possible to have hereditary forms of blood disorders presenting across the lifespan, it is more likely that each patient bringing their own personal or family history of blood disorders to attention will be acknowledged and given the opportunity to pursue the etiology. A formal genetic hematology fellowship for hematologists, geneticists, and/or bioinformaticians in training is possible and would foster talent development for future discoveries and improvements in clinical care and implementation.

**Access**

Access to both germline and acquired genetic testing in MDS must be improved. Access in this context is multipronged from access to clinicians at the bedside who recognize whom to test and either are comfortable with informed consent and navigating the entire testing process or are willing to make the connection to someone who is. Access also requires the ability to collect appropriate samples, such as skin fibroblasts or hair follicles for germline tests, as well as laboratories providing affordable assays with comprehensive and up to date gene lists, focused hereditary and acquired hematology genetics expertise to maximize interpretation potential, and turnaround times relevant for the care of patients with urgent diagnoses. Access also requires financial investment from insurance companies, hospitals, and/or governmental agencies willing to provide coverage to pay for testing to avoid financial toxicity to patients. Finally, access requires systems change to allow all of this to happen seamlessly in the clinic so it can more easily be incorporated into already complex care needs and make it more likely that many practitioners can adopt genetic testing into their own practices.

**Collaboration**

Inherent in understanding the clinical and functional significance of each individual genetic variant is studying it in as many people in diverse ethnic backgrounds as possible. However, with increasing regulation and restrictions being placed on data and sample sharing across international lines, our field will need to get creative to maximize utility of data gathered from individual families across the world. Formulating and adhering to consensus clinical care guidelines that can then be regularly reassessed with objective data would hasten evidence-based clinical management progress. Clinical and research teams agreeing on what key variables to collect over time and uniform data formats would make analysis of data across sites easier. Adopting methods used in other fields, like federated data networks that allow analysis of data across sites without actually moving the data out of an individual site, may be helpful. Seeking out and encouraging thought leaders in fields like data science and engineering to get involved in hematology could further inform new methods.

**Research**

Many key questions still remain to be answered. Clinically, despite a growing gene list, only about 30% of familial MDS/AML cases like our case presented here will be explained by currently known syndromes. Thus, what other genes and their variants contribute to MDS/AML risk? In familial MDS/AML as in other hereditary cancer syndromes such as hereditary breast cancer susceptibility, the genes with the largest effect on susceptibility and those that account for the greatest proportion of cases will be the easiest to find. Figuring out the very rare or the variants that only increase risk by a small to moderate amount and are, therefore, more common in the population will be much harder. For example, heterozygous pathogenic or likely pathogenic variants in genes that usually cause MDS/AML predisposition in the homozygous or compound heterozygous state, such as those in the Fanconi anemia or telomere biology disorder pathways or even SBDS are being found more frequently than expected by chance in patients with MDS/AML. Are these actually contributors to MDS/AML risk and if so, by how much do they increase risk?

Biologically, why does a particular germline mutation increase risk of MDS/AML and by how much is the lifetime risk elevated? What is/are the triggering event(s) that lead from the at-risk state to overt MDS/AML? From what source(s) do these triggers arise (e.g. are DNA damaging events due to endogenous cell metabolism-related exposures or are they from external exposures like smoking)? How can we intervene on this process to prevent MDS/AML or at least slow progression?

A few recent studies have begun to shed light on effects of the mutations themselves. For example, clonal hematopoiesis (CHIP) is a known marker of future MDS/AML risk. However, the actual initiating events in this process have remained unclear. A recently described autosomal recessive familial MDS/AML syndrome caused by biallelic or compound heterozygous mutations in MBD4 has highlighted the role of DNA repair on CHIP initiation and MDS/AML risk. Specifically, MBD4 is a DNA glycosylase involved in repairing methylation damage through the base excision repair pathway. Without this gene, there is a remarkable accumulation of C>T transition mutations. Interestingly, DNMT3A appears particularly affected with multiple different DNMT3A clones found in the blood and a resulting AML with myelodysplastic related changes with a remarkably high mutational burden overall. This syndrome is unique in its more direct link to a specific DNA repair deficit as a major contributor to the CHIP initiating event(s). Recent work in several other inherited bone marrow failure syndromes has also highlighted syndrome-specific CHIP features that inform underlying pathogenesis. For example, a high proportion of individuals with Shwachman Diamond syndrome develop TP53-mutated...
CHIP, often with multiple different TP53 mutated clones, by the age of 20\textsuperscript{33} whereas individuals with FPD who carry a germline RUNX1 mutation also develop early-onset CHIP, but involving many different genes.\textsuperscript{29} Further study into the exact inciting events in CHIP initiation whether stochastic or exacerbated by specific endogenous or exogenous exposures will undoubtedly advance our understanding of pathogenesis and get us closer to the goal of prevention.

**CONCLUSIONS**

Translation to improving familial myeloid malignancy predisposition assessments and syndrome-specific care for all patients in diverse, real-world, international clinical practice settings will take major efforts to improve access, education, clinical tools, policy, and collaboration. Forward progress on many of these areas is noticeable and provides hope that we will reach a future where prevention of MDS/AML is possible.

**REFERENCES**


On behalf of the MDS Foundation and our Board of Directors, THANK YOU for joining our Breakfast Satellite Symposium!

Our professional MDS Symposium at the American Society of Hematology Conference – A great start!!

THE PRESENTATIONS ARE NOW AVAILABLE ON OUR WEBSITE AT
UPCOMING MEETING

2ND REGIONAL SYMPOSIUM ON MDS – ISRAEL 2020

THE PRESENTATIONS ARE NOW AVAILABLE ON OUR WEBSITE AT:
https://www.mds-foundation.org/professional-learning-center/#2ndregionalsymposium

THANK YOU TO ALL WHO ATTENDED!

UPCOMING MEETING

XVI URUGUAYAN HEMATOLOGY CONGRESS

28 – 30 OCTOBER 2020

RADISSON HOTEL
MONTEVIDEO – URUGUAY

POSTPONED TO SEPTEMBER 1, 2021

Xi Uruguayan Hematology Congress

CONTACTS
secretaria@grupoglam.org
LATEST NEWS REGARDING THE MOLECULAR MUTATION PROJECT OF THE IWG-PM

IWG-PM/MOLECULAR PROJECT

In patients with MDS, TP53 mutations associate with high-risk presentation, complex karyotype, acute myeloid leukemia (AML) progression and poor response to hematopoietic stem cell transplantation. These findings highlight the relevance of TP53 as a prognostic and predictive biomarker. Despite the central role of TP53 in MDS, the clinical implications of TP53 mutations in the context of allelic state have not been extensively studied. Under the auspices of the International Working Group for Prognosis in MDS Molecular project (IWG-PM/Molecular) investigational efforts generated data from which an abstract was presented at the ASH 2019 meeting describing results obtained from sequencing marrow or blood samples from a representative cohort of 3,324 peri-diagnosis MDS patients on a next generation sequencing (NGS) panel along with a validation cohort from a Japanese MDS sample compendium.1

Data analysis of this study segregated patients into two TP53 states: a mono-allelic state where one wild type allele remained (33% of TP53 mutated patients, n=126); and a multi-hit state where TP53 was altered multiple times by either mutations, deletions or cnLOH (67% of TP53 mutated patients, n=254). The findings demonstrated that TP53 state was associated with clinical presentation and outcomes. Mono-allelic TP53 patients had more favorable disease than multi-hit TP53 patients and were enriched in low risk WHO subtypes. Critically, multi-hit TP53 associated with worse overall survival as compared to mono-allelic TP53 and with more pronounced AML transformation. These findings indicated that TP53 status is a critical candidate for incorporation into molecularly informed risk stratification schemas (molecular IPSS-R). Thus, TP53 mutation state is important for MDS risk estimation, disease monitoring and future correlative research.

The IWG-PM/Molecular group project is ongoing with plans for further development of a global classification schema for MDS (IPSS-R/molecular). This issue was further discussed at the MDS Foundation Symposium at ASH 2019.2

SF3B1 MUTATED MDS AS A DISTINCT DISEASE SUBTYPE PROJECT

A large body of evidence indicates that in MDS, the SF3B1 mutation is closely associated with ring sideroblasts and ineffective erythropoiesis and is characterized by less aggressive clinical course. The available evidence supports recognition of SF3B1-mutant MDS as a distinct nosologic entity. To further validate this, Dr. Malcovati and colleagues interrogated the dataset of the IWG-PM. Based on these findings, the following diagnostic criteria for the MDS with mutated SF3B1 was proposed as a distinct MDS subtype: (i) cytopenia defined by standard hematologic values; (ii) somatic SF3B1 mutation; (iii) isolated erythroid or multilineage dysplasia; (iv) the presence of any ring sideroblasts; (v) bone marrow blasts <5% and peripheral blood blasts <1%.3

IWG-PM: THERAPY-RELATED MDS PROJECT

In the current WHO classification, therapy-related Myelodysplastic Syndromes (t-MDS) are placed together with therapy-related Acute Myeloid Leukemia (t-AML) and Myeloproliferative Neoplasms (t-MPN) into one subgroup (t-MN) independent of morphological or prognostic features. Drs Kuendgen, Nomdedue, Tuechler and colleagues have assembled a database including 2,087 t-MDS patients from different international MDS groups to evaluate current classification and prognostic tools.4,5 Cytogenetic data was reviewed and strict selection criteria with regard to completeness were applied. They analyzed and compared 1,245 t-MDS patients to 4,593 primary MDS (p-MDS) patients represented in the IWG-PM database. These data demonstrated that the IPSS-R and WPSS-R separated t-MDS patients into differing risk groups effectively and indicated that all established prognostic risk factors for p-MDS maintained relevance for t-MDS, with cytogenetic features having enhanced predictive power. Poorer clinical outcomes occurred in each t-MDS
compared to p-MDS subgroups. Despite t-MDS being considered as having a uniformly poor prognosis these data demonstrated differing outcomes for each t-MDS subgroup. Given these data, these findings suggest the ability and need for classifying t-MDS as a separate entity and distinct from the other WHO classified t-myeloid neoplasms (t-MNs). This terminology would enable more reasonable treatment decisions and facilitate the inclusion of t-MDS patients into clinical studies.

REFERENCES

2. Papaemmanuil E, Classification and personalized prognosis in MDS. MDS Foundation Symposium, ASH meeting, 2019 Orlando, December.
The first investigator driven, multinational MDS/MPN-specific trial in the world is led by the MDS/MPN IWG. ABNL MARRO – A Basket Trial of Nole therapy combinations in untreated MDS/MPN And Relapsed/Refractory Overlap Syndromes (ABNL-MARRO) – is an international study designed to quickly test new compounds and combinations of therapy at referral centers within the MDS/MPN IWG which see MDS/MPN patients, study the biology and pathophysiology of the diseases, and have multilateral expertise in this area.

ABNL MARRO-001 is the first MDS/MPN IWG study and has been approved by the FDA. ABNL MARRO-001 uses an oral DNA methyltransferase inhibitor (DNMTi), ASTX727, as a backbone with combination therapies targeting JAK1, PIM kinase and LSD-1. DNMTi combinations have been evaluated in phase 1 safety studies, and will form 3 separate arms in ABNL MARRO-001. With ABNL MARRO-001, the MDS/MPN IWG aims to validate the proposed criteria for response in MDS/MPN, test QOL tools in patients with MDS/MPN, develop new biomarkers for response to therapy, and augment efforts of large scale prospective genotyping efforts in MDS/MPN. This infrastructure will allow for ABNL-MARRO-002, -003, and so on, to quickly offer new therapies to patients with MDS/MPN.
DO YOU KNOW YOUR MDS SUBTYPE AND IPSS-R SCORE?

We launched a recent survey which showed that only 50% of patients know their subtype and only about 30% know their IPSS-R Score. Your subtype and IPSS-R score determine your personalized treatment plan.

Knowing your subtype and IPSS-R score can help guide discussions with your doctor.

ASK YOUR HEALTHCARE TEAM...

Knowing your IPSS-R score and MDS subtype can guide discussions with your healthcare team about the best treatment options for you!

KNOW YOUR SCORE

The IPSS-R is a classification system used by doctors to help predict a person’s risk of developing AML and overall survival without treatment.

CATEGORIES & SCORES

<table>
<thead>
<tr>
<th>Score</th>
<th>Score Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very Low</td>
<td>≤1.5</td>
</tr>
<tr>
<td>Low</td>
<td>&gt;1.5 - 3</td>
</tr>
<tr>
<td>Intermediate</td>
<td>&gt;3 - 4.5</td>
</tr>
<tr>
<td>High</td>
<td>&gt;4.5 - 6</td>
</tr>
<tr>
<td>Very High</td>
<td>&gt;6</td>
</tr>
</tbody>
</table>

KNOW YOUR SUBTYPE

MDS is classified into several different subtypes based on the following features:

- Blood cell counts
- Percentage of blasts in the bone marrow
- Cytogenetics

**FAB SUBTYPES**
- Refractory Anemia (RA)
- Refractory Anemia with Ringed Sideroblasts (RARS)
- Refractory Anemia with Excess Blasts (RAEB)
- Refractory Anemia with Excess Blasts in Transformation (RAEB-t)
- Chronic Myelomonocytic Leukemia (CMML)
- Acute Myeloid Leukemia (AML)

**WHO SUBTYPES**
- MDS with single lineage dysplasia
- MDS with ring sideroblasts (MDS-RS)
- MDS-RS and single lineage dysplasia
- MDS-RS and multilineage dysplasia
- MDS with multilineage dysplasia
- MDS with excess blasts
- MDS with isolated del(5q)
- MDS, unclassifiable
- Provisional entity: Refractory cytopenia of childhood

More detailed information on IPSS-R scores and subtype can be found online in our Building Blocks of Hope resource.
MDS FOUNDATION LEADERSHIP

BOARD OF DIRECTORS
Pierre Fenaux, MD
Hôpital St Louis, Université Paris 7
Peter L. Greenberg, MD
Stanford University School of Medicine
Sandra E. Kurtin, PhD, ANP-C, AOCN
The University of Arizona Cancer Center
Alan F. List, MD
Tampa, Florida
Luca Malcovati, MD
University of Pavia School of Medicine

Stephen D. Nimer, MD, Chair
Sylvester Comprehensive Cancer Center
Michael Savona, MD
Vanderbilt University School of Medicine

MEMBERS EMERITUS
John M. Bennett, MD
Rochester, New York
Eva Hellström-Lindberg, MD, PhD
Stockholm, Sweden
Charlotte M. Niemeyer, MD
Freiburg, Germany
Franz Schmalzl, MD, Innsbruck, Austria

OFFICERS
Stephen D. Nimer, MD, Chair
Tracey Iraca, Executive Director
Sandra E. Kurtin, PhD, ANP-C, AOCN, Treasurer
Janice Butchko, Secretary

MEDICAL AND SCIENTIFIC ADVISORY BOARD
Rafael Bejar, MD, PhD
Moore’s Cancer Center
at the University of California, San Diego
Rena Buckstein, MD, FRCP
Sunnybrook Health Sciences Centre
Mario Cazzola, MD, Chair
University of Pavia School of Medicine
Fondazione IRCCS Policlinico San Matteo
Jane Churpek, MD, MS
UW Carbone Cancer Center
University of Wisconsin
School of Medicine and Public Health
Theo J.M. de Witte, MD, PhD
Radboud University Nijmegen Medical Centre
Nijmegen Centre of Molecular Life Sciences
Erin P. Demakos, RN, CRN
Icahn School of Medicine at Mount Sinai
Benjamin Ebert, MD, PhD
Dana-Farber Cancer Institute

Silvia M. M. Magalhães, MD, PhD
Federal University of Ceará
Hospital Universitário Walter Cantídio
Moshe Mittelman, MD
Tel-Aviv Sourasky Medical Center
Yasushi Miyazaki, MD
Nagasaki University
Ghulam J. Mufti, DM, FRCP, FRCPath
King’s College London & King’s College Hospital
Seishi Ogawa, MD, PhD
Kyoto University
Uwe Platzbecker, MD
Universitätsklinikum Carl Gustav Carus
Guillermo Sanz, MD
Hospital Universitario y Politecnico La Fe
Akiko Shimamura, MD, PhD
Dana-Farber Cancer Institute
Lewis R. Silverman, MD
Icahn School of Medicine at Mount Sinai

INTERNATIONAL NURSE LEADERSHIP BOARD
Erik Aerts, RN
Zürich, Switzerland
Angelika Bitter
Dresden, Germany
Claudia Boglione, RN
Florence, Italy
Karen Campbell, RN
Edinburgh, Scotland, United Kingdom
Hwang Chung Cheng Jordan
Singapore
Nancy Corbitt BSN, RN, OCN, CRNI
Baltimore, Maryland, United States
Nicole Crisp, RN, BScN, MN, NP-adult
Edmonton, Alberta, Canada
Lucy Cussans, RN
North Terrace, Adelaide, Australia
Erin Demakos, RN, CRN
New York, New York, United States
Rebecca Dring, RN
Melbourne, Australia
Corien Eeltink, RN, MA ANP
Amsterdam, The Netherlands

Lenn Fechter, RN
Stanford, California, United States
Janet Hayden, RN, BSc(hons), MPH
London, United Kingdom
Amelia Hodson, BSN, RN, Clinician II
Charlottesville, Virginia, United States
Miki Iizuka, RN
Tokyo, Japan
Jacqueline Jagger, BA, RN
Gosford, Australia
Natasha L. Johnson, MS, APRN, AOCNP
Tampa, Florida, United States
Sandra E. Kurtin, PhD, ANP-C, AOCN
Tucson, Arizona, United States
Petra Lindroos Kolqvist, RN
Goteborg, Sweden
Arno Mank, RN, PhD
Amsterdam, The Netherlands
R. Denise McAllister, MS, ARNP, AOCNP
Clearwater, Florida, United States
Cindy Murray, RN, MN, NP-adult
Toronto, Ontario, Canada

Geke Ong, RN
London, United Kingdom
Phyllis Paterson, RN, RSCN, Dip Onc
Cambridge, United Kingdom
Jean A. Ridgeway, DNP, APN, NP-C, AOCN
Chicago, Illinois, United States
Natalie Singer, MSc, RN, BSc(Hons)
Glasgow, Scotland, United Kingdom
Samantha Soggee, RN, MN
Heidelberg, Victoria, Australia
Amber Thomassen, AGPCNP-BC, AOCNP
Miami, Florida, United States
Sara M. Tinsley, PhD, ARNP, AOCN
Tampa, Florida, United States
Catherine Vassili, RN, MN
Victoria, Australia
Lauren Ziskind, MSN, NP-C, FNP-BC, OCN
Chicago, Illinois, United States

DEVELOPMENT BOARD
Stuart Goldberg, MD
John Theurer Cancer Center at Hackensack University Medical Center, MDS Specialist
Jennifer Keam, MD, MPH
MDS Caregiver
Deborah Peirce, Chair
Talent/Leadership and Organizational Development Executive, MDS Caregiver
Julia McGuire, Advisor
Executive Vice President, Campbell & Company
Madeleine’s Mom, MDS Patient
Dear Friends of the MDS Foundation,

We understand that during the uncertainty of this pandemic, the main concern of all is protecting yourself as well as your families and friends from exposure to the COVID-19 virus. The highest priority of the MDS Foundation at this time, and always, is the health and safety of our community. With this in mind, and in consultation with medical professionals, we have decided to postpone our upcoming MDS Awareness Walks in Chicago and New York City. We are waiting for permits to be finalized, but we are hoping to reschedule the walks for early Fall. Look to our website and facebook for updates on our MDS Awareness Walks which may be going virtual due to the coronavirus pandemic. We can’t come together as a community in person, but that doesn’t mean we can’t make a difference individually. This situation is continuously evolving and we will evaluate any further developments as they come. We will send out another email once we have confirmed the new dates. In the meantime, should you want to support the walks or set up a team, please visit https://www.mds-foundation.org/mds-awareness-walk/.

We appreciate your continued support and thank you for understanding as we navigate the current situation.

Best wishes during this difficult time.

Tracey Iraca, Executive Director
HIGHLIGHTS OF LATEST LITERATURE IN MDS

SUNEEL D. Mundle, PhD
Rhea Mundle

Listed below are citations of some new publications relevant to MDS (pathogenesis, clinical characterization, management, etc.). To access the complete articles log on to www.pubmed.gov.

EPIDEMIOLOGY, DIAGNOSIS AND PROGNOSIS:

   The meta-analysis included 12 studies with 2236 MDS patients. A pooled HR for overall survival and leukemia free survival showed significantly adverse prognostic impact of DNMT3A mutations, (OS- HR=1.65, p<0.001; LFS- HR=4.62, p<0.001)

   Using a pre-established clinical trial database and linear regression analysis of 25 trials with 38 cohorts, the authors found that ≥PR (PR+CR+Marrow CR) was a strong predictor of OS (adjusted R²=0.64). Furthermore, for a given response rate (≥PR) or treatment group, the survival was longer in treatment naïve vs previously treated patients.

   Data on 47 men and 37 women aged ≥85 yrs demonstrated that 93% patients were anemic at diagnosis with a med Hb level of 9.5g/dL. Sixty four percent of patients had more than one cytopenia, 53% patients had elevated serum ferritin levels, and 88% patients had one or more significant comorbidities (cardiac, renal, or diabetes). Of the patients with significant anemia (Hb <10 g/dL), 42% received erythropoietin. Of the 29 transfusion-dependent patients only 48% received erythropoietin. The AML transformation rate was 7%. The median overall survival was 16 mo in men and 27 mo in women. In 34 patients with IPSS-R classification, the med survival was 31.5 mo in very good risk, 41.5 mo in good risk, and 8mo in int risk patients.

   A frailty Index (FI) based on impact of deficits on likelihood of adverse outcomes was calculated in 440 MDS patients. The median FI was 0.25 and FI was correlated with age, IPSS-R risk. The FI ≤0.2 vs >0.2-0.3 vs >0.3 demonstrated significantly different OS with a median 55.6 mo, 24 mo and 10.9 mo respectively (p<0.0001). FI remained as a significant covariate of OS in a multivariate analysis as well. Additionally, FI discriminated OS within each of the IPSS-R/R categories.

TREATMENT:

RBC Transfusion and Growth Factors:

   This multinational study randomized 38 patients in outpatient clinic to initiate RBC transfusion at standard threshold of Hb ≤8.0 g/dL (n=20) vs a liberal threshold of Hb ≤10.5 g/dL (n=18). The compliance for transfusion threshold was 86% vs 99% in the standard vs liberal groups and the mean pre-transfusion Hb was 8.0 g/dL and 9.7 g/dL respectively. Using EORTC QLQ-C30 and EQ-5D-5L tools, the quality of life was found to be better in patients on liberal Hb threshold arm.

   The analysis based on European MDS registry included 1267 lower risk MDS

The Ontario AZA-MDS registry linked to population based administrative databases showed approx. 80% patients (705/877) had at least one emergency clinic visit; 33% in their first cycle. Also, approx. 77% had at least one hospitalization with a mean length approx. 18 days. A greater comorbidity, non-response to AZA and transfusion dependence were associated with both emergency room visits and hospitalizations. Also, among patients with ≥3 cycles of treatment hospitalization during first cycle was associated with an increased risk of death.


The authors argue that there continues to exist an unmet need to improve upfront treatment of higher risk MDS patients as only a proportion of patients respond to hypomethylating agents and the responses are less durable. Authors propose upfront combinations with other agents as a way to improve outcomes of HMA and list venetoclax and rigosertinib as promising agents for such combination.


This was a retrospective study with 133 MDS patients. The study demonstrated that in real world patients 15 mg/m²/day dose vs. 20mg/m²/day dose resulted in a comparable response rates (ORR-51.8% vs 52%, CR-15.7% vs 22% respectively), longer survival (21.6 mo vs 15.2 mo respectively), and lower hematologic toxicity (Gr3/4 neutropenia – 60% vs 88%; thrombocytopenia – 65% vs 88% respectively).

Additionally, the report also found that the overall survival benefit with 15 mg/m²/day was primarily associated with lower risk patients.


An azacytidine treatment intensification tested using a schedule leading to 20% higher number of days with azacytidine (75 mg/m²/day x 5 days in 14-day cycle) administration during first 8 weeks of treatment. Patients who achieved CR/PR received additional aza at 21-day cycles x 4 followed by std 7-day dosing in a 28-day cycle until progression. For patient not achieving CR or PR after first 8 weeks, additional 8 weeks of intensified treatment was given. The primary end point was response by IWG 2006 criteria after first 4 and 8 dose intensified cycles (15-day cycles). The int2- and high-risk proportions were 65:35 among the 26 evaluable patients. The overall marrow response after 4- or 8-weeks intensified treatment was 22% (6/27). The narrow CR+ hematologic improvement (HI) was 65% after week 4 and 62% after week 8. With a f/u of approx. 42 mo, median duration of CR/PR was 10.5 mo, duration of overall response was 14 mo, and overall survival was 21.5 mo. Treatment intensification was not associated with increased toxicity.

5. Zeidan A, et al. Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes. Leuk Lymphoma,
A US claims database study (Inovalon MORE2 registry) comparing outcomes of treatment sequence Len-HMA vs HMA-Len demonstrated longer time to discontinue second treatment (HR-0.52, p=0.023), and to disenroll from insurance used as proxy for survival (HR-0.64, p=0.017).

Novel Therapies:
   The review evaluates challenges to drug development and emphasizes the meaningfulness of study end points relevant to patients. The report also underscores the importance of assessing longer term end points such as response duration, quality of life and overall survival in addition to the currently common end points of hematologic and bone marrow response rates.

Patient Reported Outcomes:
   Although PRO measurement is less common in clinical studies in MDS, when conducted have demonstrated positive results with growth factors, HMS and IMiDs. Many new clinical studies have begun to incorporate a prospective PRO assessment using broad metrics such as EORTC-QLQ-C30, the previously reported FACT-An and MDS specific tools like QUALMS (Quality of life in Myelodysplasia Scale).

Reviews, Perspectives & Guidelines:

A special thanks to Suneel and Rhea Mundle for their great efforts in monitoring these important MDS peer-review publications.
ERYTHROPOIESIS AND RING SIDEROBLASTS: WHAT DOES THAT MEAN FOR MDS PATIENTS?

SARA M. TINSLEY, PHD, ARNP, AOCN
Malignant Hematology
Nurse Practitioner
H. Lee Moffitt Cancer Center
Tampa, Florida, United States

Erythropoiesis is the term for producing red blood cells from the hematopoietic stem cells to circulating mature red blood cells. This occurs in the bone marrow, and is quite a complex process producing over 10 billion red blood cells hourly under normal conditions to maintain stable hemoglobin levels. 1

In myelodysplastic syndromes (MDS), erythropoiesis is defective resulting in anemia; a hallmark of the disease. 2 The majority of patients diagnosed with MDS will become dependent on red blood cell transfusions. 3 One of the goals of treatment with lower-risk MDS (LR-MDS), defined as very low, low, or intermediate on the revised international prognostic scoring system (<3.5 points) 4 , is to minimize the number of red blood cell transfusions and improve quality of life.

Current treatments for LR-MDS are focused on treatment of anemia with recent improvements in the understanding of ineffective erythropoiesis. There are two areas of primary interest, early stage and a later stage, focused on terminal erythroid maturation into red blood cells. 5 Erythroid stimulating agents (ESA), such as epoetin alpha and darbepoetin alpha, are frequently first-line treatment for anemia in LR-MDS, targeted toward early stage erythropoiesis. Specific criteria are used to determine patients who will likely benefit from ESAs. Criteria include low transfusion burden (<2 units per month) and an erythropoietin level < 500 u/L. 6 Response rates to ESAs overall are between 20 and 40%. Patients usually respond for 18–24 months. For patients with deletion of 5q, lenalidomide is the standard of care with a 67% response rate that normally lasts about 3 years. 7 Various sites of differentiation have been postulated for lenalidomide. 8

On April 3, the Food and Drug Administration approved luspatercept (REBLOZYL, Celgene Corporation) for the treatment of anemia in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RST) who have failed treatment with erythroid stimulating agents and required 2 or more units of packed red blood cells in an 8-week period. Luspatercept works further along in the pathway of red blood cell development than prior treatments. In clinical trials, side effect profile included fatigue, diarrhea, nausea, anemia, dizziness and back pain. 9 Luspatercept is given subcutaneously every 3 weeks and is dosed at 1 mg/kg. Response rates varied among the clinical trials for reduction in number of red blood cells transfused. However, approximately 40% of patients experienced improvement with reduction in the number of red blood cells needed. This is an exciting time with a new treatment now available for the treatment of anemia in MDS!

REFERENCES

CORD BLOOD REGISTRY: PROVIDING CORD BLOOD BANKING TO FAMILIES IN NEED

ELIZA STROH, MS, LGCG
Cord Blood Clinical Specialist at Cord Blood Registry

Cord blood is a rich source of blood forming stem cells (called hematopoietic stem cells or HSCs). For more than 20 years, cord blood has been used as a source of stem cells for patients requiring a stem cell transplant as part of their treatment for bone marrow failure conditions, like the myelodysplastic syndromes (MDS), as well as other hematological diseases and malignancies. To date, more than 40,000 cord blood stem cell transplants have been performed worldwide. In transplant medicine, HSCs are used to regenerate the patient’s blood and immune systems after chemotherapy and/or radiation treatments have been given to suppress or ablate the patient’s own blood and immune systems.

Cord blood HSCs have advantages over other sources of HSCs, such as those derived from bone marrow, including a lower risk of graft-vs-host disease, which can be a serious side effect of HSC transplants. Depending on the condition being treated, the stem cells used in a transplant may come from a healthy donor or from the patient themselves. In treating patients with MDS, the stem cells typically come from a healthy donor, preferably a sibling who is a good genetic match to the patient. Using stem cells from a closely matched relative helps to improve transplant outcomes.

Cord blood stem cells can be collected and stored at the time of birth and either donated to a public cord blood bank for use by an anonymous patient in need or stored in a private bank for potential use within the family. Cord Blood Registry® (CBR®) is the largest and most experienced family cord blood bank. We offer cord blood collection, processing and storage services to families who wish to save their children’s cord blood at the time of birth for the family’s potential use in the future. By saving cord blood at the time of birth, families can ensure that they have access to this important resource should anyone in the immediate family ever require a HSC transplant. Many patients with hematological conditions, including MDS, have no family history of the condition, and therefore banking at the time of birth provides a “safety-net” for families. In fact, current estimates suggest that, over an individual’s lifetime, the odds of requiring an HSC transplant are 1 in 217. When stored under the proper conditions, cord blood stem cells are expected to last indefinitely, providing a long-term resource for families’ potential use.

As part of CBR’s commitment to families in need, our Newborn Possibilities Program® offers cord blood processing and 5 years of storage at no cost for families in which a parent or full sibling of the newborn is diagnosed with a condition for which HSC transplant may be a treatment option. This program provides families with access to a potential source of valuable stem cells, should a transplant be required. To date, CBR has enrolled more than 8,000 families into the Newborn Possibilities Program. Though MDS is typically diagnosed in individuals past child bearing age, families with MDS are eligible to apply for the program. In addition, CBR has Genetic Counselors on staff to help families make informed choices about their newborn stem cell banking options and to answer questions regarding medical indications for cord blood banking.

For more information about Cord Blood Registry or the Newborn Possibilities Program please call us at 1-888-cordblood or visit www.cordblood.com.
MDS CENTERS OF EXCELLENCE

Our MDS Centers of Excellence are institutions that meet the highest standards for diagnosis, treatment and patient care. These centers help patients seeking first or second opinions and/or additional treatment options from experts in MDS. We currently have 72 Centers in the United States and 112 Centers in countries around the world. Our MDS Centers can be viewed here: https://www.mds-foundation.org/mds-centers-of-excellence

BENEFITS OF MEMBERSHIP:
- MDSF CoEs form the referral base for the patients who contact the Foundation daily.
- MDSF CoEs are proudly recognized on the Foundation website, within our printed newsletters, and through our various social media platforms.
- MDSF CoEs are offered reduced registration rates at our Intl’l Symposia and discounted subscription rates to Leukemia Research.
- MDSF CoEs have full access to MDSF educational resources for distribution to your patients.
- In addition, along with your $500 CoE renewal payment, your annual MDSF Professional Membership dues are waived.
- MDSF Professional Members are also listed, by name, on our website and in our printed newsletters.
- The work of your institution can be shared with our patient and professional contacts via our website and/or our social media channels. We can spread the word of your clinical trials, research projects, etc.

Would you like your treatment center to become part of the referral system for MDS patients and be designated as a Center of Excellence?

To be recognized as a Center of Excellence, an institution must have the following:
- An established university (or equivalent) program
- Recognized morphologic expertise in MDS
- Available cytogenetics and/or molecular genetics
- Ongoing research, including Institutional Review Board–approved clinical trials
- Documentation of peer-reviewed publications in the field

Please contact the Foundation for further information and an application form for your center.

The following centers have qualified as MDS Centers of Excellence:

### UNITED STATES

**ALABAMA**

University of Alabama at Birmingham
Birmingham Comprehensive Cancer Center
Birmingham, Alabama
Kimo Bachiaashvili, MD

**ARIZONA**

Mayo Clinic Hospital
Phoenix, Arizona
Cecilia Arana Yi, MD/Lisa Sproat, MD

The University of Arizona Cancer Center
Tucson, Arizona
Ravi Krishnaswami, MD, FACP

**CALIFORNIA**

Cedars-Sinai Medical Center
UCLA School of Medicine
Los Angeles, California
H. Phillip Koehler, MD

City of Hope National Medical Center
Duarte, California
Stephen J. Forman, MD

Moores Cancer Center–UC San Diego Health
San Diego, California
Rafael Bejar, MD, PhD
Peter Curtin, MD

Stanford University Medical Center
Stanford, California
Peter L. Greenberg, MD

UCLA Health Hematologic Malignancies and Stem Cell Transplant Program
Los Angeles, California
Gary J. Schiller, MD

University of Southern California
Keck School of Medicine
Los Angeles, California
Casey L. O’Connell, MD

**COLORADO**

University of Colorado School of Medicine
University of Colorado Cancer Center
Aurora, Colorado
Daniel Aaron Pollyea, MD, MS

**CONNECTICUT**

Yale Cancer Center/Smilow Cancer Hospital
Yale University School of Medicine
New Haven, Connecticut
Amer Zeidman, MD

**FLORIDA**

Mayo Clinic
Jacksonville, Florida
James M. Foran, MD

Moffitt Cancer Center
Tampa, Florida
Rami Komrokji, MD

 Sylvester Comprehensive Cancer Center
University of Miami, Miller School of Medicine
Miami, Florida
Stephen D. Nimer, MD

**GEORGIA**

Emory Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
Amelia Langston, MD

The Blood and Marrow Transplant Program at Northside Hospital
Atlanta, Georgia
Asad Bashey, MD

**ILLINOIS**

Loyola University Chicago
Cardinal Bernardin Cancer Center
Maywood, Illinois
Scott E. Smith, MD, PhD

Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Feinberg School of Medicine
Chicago, Illinois
Olga Frankfurt, MD

Rush University Medical Center
Chicago, Illinois
Jamile Shammo, MD

University of Chicago Medical Center
Chicago, Illinois
Richard A. Larson, MD

University of Florida
Shands Hospital
Gainesville, Florida
Christopher R. Cogle, MD
INDIANA
Indiana University Simon Cancer Center
Indianapolis, Indiana
Larry Cripe, MD/Hamid Sayar, MD, MS

IOWA
The University of Iowa Hospitals
and Clinics, Holden Cancer Center
Iowa City, Iowa
Carlos E. Vigil-Gonzales, MD

KANSAS
The University of Kansas Cancer Center
Westwood, Kansas
Barry Skikne, MD

MARYLAND
Johns Hopkins University School of Medicine
Baltimore, Maryland
Amy Elizabeth DeZern, MD
University of Maryland
Greenebaum Cancer Center
Baltimore, Maryland
Maria R. Baer, MD

MASSACHUSETTS
Dana-Farber/Boston Children’s Cancer
and Blood Disorders Center
Boston, Massachusetts
Akiko Shimamura, MD, PhD
Dana-Farber Cancer Institute
Boston, Massachusetts
Richard M. Stone, MD/David P. Steensma, MD
Benjamin Ebert, MD, PhD
Massachusetts General Hospital
Cancer Center
Boston, Massachusetts
Timothy Graubert, MD
Tufts University School of Medicine
Tufts Medical Center
Boston, Massachusetts
Kellie Sprague, MD

MICHIGAN
Barbara Ann Karmanos Cancer Institute
Wayne State University
Detroit, Michigan
Charles A. Schiffer, MD
William Beaumont Hospital Cancer Center
Royal Oak, Michigan
Ishmael Jaiyesimi, DO

MINNESOTA
Mayo Clinic
Rochester, Minnesota
Mark R. Litzow, MD
University of Minnesota
Medical Center, Fairview University
of Minnesota Medical School
Minneapolis, Minnesota
Erica D. Warlick, MD

MISSOURI
Washington University School of Medicine
Siteman Cancer Center
St. Louis, Missouri
John F. DiPersio, MD, PhD

NEBRASKA
University of Nebraska Medical Center
Omaha, Nebraska
Lori Maness, MD

NEW HAMPSHIRE
Dartmouth-Hitchcock Medical Center
and Norris Cotton Cancer Center
Lebanon, New Hampshire
Kenneth R. Meenan, MD

NEW JERSEY
John Theurer Cancer Center at
Hackensack University Medical Center
Hackensack, New Jersey
Stuart Goldberg, MD
Rutgers Cancer Institute of New Jersey
Rutgers University Hematologic Malignancies
and Stem Cell Transplant
New Brunswick, New Jersey
Dale G. Schaer, MD, PhD

NEW MEXICO
University of New Mexico
Comprehensive Cancer Center
Albuquerque, New Mexico
Leslie Andritsos, MD

NEW YORK
Albert Einstein Cancer Center/Albert Einstein
College of Medicine of Yeshiva University
Bronx, New York
Amit Verma, MD
Columbia University Medical Center
New York, New York
Azra Razza, MD
Memorial Sloan-Kettering Cancer Center
New York, New York
Virgina M. Klimek, MD
Northwell Health Cancer Institute
at Monter Cancer Center
Lake Success, New York
Steven L. Allen, MD
Laura & Isaac Perlmutter Cancer Center
at NYU Langone Health
New York, New York
Maher Abdul Hay, MD
Icahn School of Medicine at Mount Sinai
New York, New York
Lewis R. Silverman, MD
New York Medical College/Westchester
Medical Center, Zalmen A. Arlin Cancer Center
Valhalla, New York
Karen Seiter, MD
Roswell Park Cancer Center
Buffalo, New York
Elizabeth Griffiths, MD/James E. Thompson, MD
University of Rochester Medical Center
Rochster, New York
Jane L. Liesveld, MD
Weill Medical College of Cornell University
New York Presbyterian Hospital
New York, New York
Gail J. Roboz, MD

NORTH CAROLINA
Atrium Health Levine Cancer Center
Charlotte, North Carolina
Srinivasa R. Sanikommu, MD, FACP
Michael Grunwald, MD
Duke University Medical Center
Durham, North Carolina
Carlos M. deCastro, MD
The North Carolina Cancer Hospital
University of North Carolina Lineberger
Comprehensive Cancer Center
Chapel Hill, North Carolina
Matthew Foster, MD/Brandi Reeves, MD
Wake Forest University School of Medicine
Comprehensive Cancer Center
 Winston-Salem, North Carolina
Bayard L. Powell, MD

OHIO
Cleveland Clinic Foundation
Taussig Cancer Center
Cleveland, Ohio
Jaroslav Maciejewski, MD, PhD
Mikkael Sekeres, MD, MS
Hoxworth Blood Center, George L. Strike
Bone Marrow Transplant Program
University of Cincinnati – UC Health
Cincinnati, Ohio
Zartash Gul, MD
The Ohio State Comprehensive
Cancer Center, James Cancer Hospital
and Solove Research Institute
Columbus, Ohio
James S. Blachly, MD/Alison R. Walker, MD

 PENNSYLVANIA
Allegheny Health Network Cancer Institute
Western Pennsylvania Hospital
Pittsburgh, Pennsylvania
Salman Fazal, MD
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Philip Pancari, MD
University of Pennsylvania Cancer Center
Philadelphia, Pennsylvania
Selina Luger, MD
UPMC Cancer Center
Pittsburgh, Pennsylvania
Anastasios Raptis, MD/James M. Rossetti, DO
TENNESSEE
Vanderbilt University Medical Center
Nashville, Tennessee
Sanjay Mohan, MD/Michael R. Savona, MD

TEXAS
Texas Oncology – San Antonio
San Antonio, Texas
Roger M. Lyons, MD, FACP
Texas Oncology, Midtown
Austin, Texas
Richard Helmer, III, MD
University of Texas
MD Anderson Cancer Center
Houston, Texas
Guillermo Garcia-Manero, MD
Hagop Kantarjian, MD
University of Texas
Southwestern Medical Center
Dallas, Texas
Robert H. Collins, Jr., MD, FACP

UTAH
University of Utah Huntsman Cancer Institute
Salt Lake City, Utah
Paul J. Shami, MD

VIRGINIA
University of Virginia
Charlottesville, Virginia
Michael Keng, MD

WASHINGTON
Fred Hutchinson Cancer Research Center
University of Washington
Seattle Cancer Care Alliance
Seattle, Washington
Joachim Deeg, MD/Elihu Estey, MD

WASHINGTON, DC
Georgetown University Hospital
Lombardi Comprehensive Cancer Center
Washington, D.C.
Catherine Broome, MD
George Washington University
VA Medical Center
Washington, D.C.
Charles S. Hesdorffer, MD

WISCONSIN
American Family Children’s Hospital
University of Wisconsin Health
Madison, Wisconsin
Inga Hofmann, MD
Medical College of Wisconsin
Bone Marrow Transplant Program
Milwaukee, Wisconsin
Parameswaran Hari, MD
University of Wisconsin
Madison Medical School
Madison, Wisconsin
Mark B. Juckett, MD

OUTSIDE THE UNITED STATES

ARGENTINA
Sanatorio Sagrado del Corazón
Buenos Aires, Argentina
Marcelo Lastrebrner, MD

ARMENIA
Muratsan University Hospital
Complex of Yerevan State Medical University
Yerevan, Armenia
Gevorg Tamanyan, MD

AUSTRALIA
Cabiri Haematology & Oncology Centre
Melbourne, Australia
Melita Kenealy, MD
Monash Health Monash University
Clayton, Victoria, Australia
Jake Shortt, BMEdSc, MBCHB FRACP FRCPA PhD
Peter MacCallum Cancer Institute
University of Melbourne
East Melbourne, Australia
John F. Seymour, MD
The Royal Melbourne Hospital
Parkville, Victoria, Australia
David Ritchie, MD

AUSTRIA
Hansch Hospital
Medical University of Vienna
Vienna, Austria
Michael Pleilstöcker, MD
Medical University of Vienna
Vienna, Austria
Peter Valent, MD
University Hospital of Innsbruck
Innsbruck, Austria
Reinhard Stauder, MD

BELGIUM
AZ Sint-Jan AV
Brugge, Belgium
Dominik Selleslag, MD
University Hospital Leuven
Leuven, Belgium
Marielle Beckers, MD, PhD
Michel Delforge, MD, PhD

BRAZIL
AC Camargo Hospital–Cancer Center
São Paulo, Brazil
Luiz Fernando Lopes, MD, PhD
Hospital das clínicas da Faculdade de Medicina da Universidade de São Paulo
São Paulo, Brazil
Elvira D. Rodrigues Pereira Velloso, MD, PhD
Universidade Federal de Ceará
Ceará, Brazil
Silvia Maria M. Magalhães, MD, PhD
Universidade Federal de São Paulo
São Paulo, Brazil
Maria de Lourdes Chauffaille, MD, PhD

CANADA
Princess Margaret Hospital
Toronto, Ontario, Canada
Karen Yee, MD
Odette Cancer Centre
Sunnybrook Health Sciences Center
Toronto, Ontario, Canada
Rena Buckstein, MD, FRCP
Richard A. Wells, MD
St. Paul’s Hospital
Vancouver, British Columbia, Canada
Heather Leitch, MD, PhD
University of Toronto
Hospital for Sick Children
Toronto, Ontario, Canada
Yigal Dror, MD

CHINA
Guangdong General Hospital & Guangdong Academy of Medical Sciences
Guangzhou, China
Xin Du, MD, PhD
Institute of Hematology and Blood Diseases Hospital
Chinese Academy of Medical Sciences
Tianjin, China
Zhihian Xiao, MD
The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology
Jiangsu Province, China
Suning Chen, MD, PhD
The First Affiliated Hospital of Zhejiang University
Zhejiang Province, China
Xiao Li, MD, PhD

CROATIA
Clinical Hospital Merkur
Zagreb, Croatia
Inga Mandac Ragulj, MD

CZECH REPUBLIC
Institute of Hematology & Blood Transfusion
Prague, Czech Republic
Jaroslav Cermák, MD, PhD

DENMARK
Odense University Hospital
The University of Southern Denmark
Odense, Denmark
Klas Raaschou-Jensen, MD/Claus Marcher, MD
Metropolitan Research and Treatment Center for Blood Disorders (MRTC Japan)
Tokyo, Japan
Kiyoyuki Ogata, MD, FACP

Nagasaki University Hospital School of Medicine, Atomic Bomb Disease Institute
Nagasaki City, Japan
Yasushi Miyazaki, MD

Saitama Medical University International Medical Center
Hidaka, Saitama, Japan
Tomoya Maeda, MD, PhD

Tokyo Medical College
Tokyo, Japan
Kazuma Ohyashiki, MD, PhD

MEXICO
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
American-British-Cowdray Cancer Center
Mexico City, Mexico
Alvaro Aguayo, MD

THE NETHERLANDS
Radboud University Nijmegen Medical Center
Nijmegen, The Netherlands
Saskia M.C. Langemeijer, MD

Vrije Universiteit Medical Center
Amsterdam, The Netherlands
Arjan A. van de Loosdrecht, MD, PhD

POLAND
Jagiellonian University Collegium Medicum
Kraków, Poland
Aleksander Skotnicki, MD, PhD

Medical University of Warsaw
Warsaw, Poland
Krzysztof Madry, MD

PORTUGAL
Hospital de Santa Maria
Lisbon, Portugal
Joao F. Lacerda, MD

SAUDI ARABIA
King Faisal Specialist Hospital & Research Centre
Riyadh, Saudi Arabia
Amr Hanbali, MD

King Saud University
Riyadh, Saudi Arabia
Ak Almomen, MD

SINGAPORE
Singapore General Hospital
Aloysius Ho, MD

SOUTH AFRICA
University of Cape Town
Groote Schuur Hospital
Cape Town, South Africa
Nicolas Novitsky, MD, PhD

SOUTH KOREA
Catholic Blood and Marrow Transplantation Center
The Catholic University of Korea
Seoul, Korea
Yoo-Jin Kim, MD

Seoul National University Hospital
Seoul National University College of Medicine
Seoul, Korea
Dong Soon Lee, MD, PhD

Yonsei Cancer Centre, Severance Hospital
Yonsei University College of Medicine
Seoul, Korea
June-Won Cheong, MD, PhD

SWEDEN
Karolinska Institute at Karolinska University Hospital Huddinge
Stockholm, Sweden
Eva Hellström-Lindberg, MD, PhD

University Hospital Zurich
Zurich, Switzerland
Markus G. Manz, MD, Stefan Balabanov, MD

SWITZERLAND
Basel University Hospital
Basel, Switzerland
Jakob R. Passweg, MD, MS

Bern University Hospital
Bern, Switzerland
Nicolas Bonadies, MD

National University Hospital
Tampere, Finland
Matti Aho, MD, PhD

University Hospital Southampton
Southampton, Hampshire, UK
Andrew Wightman, MD

University of Sydney
Sydney, Australia
Lauren Callander, MD

University of Technology Sydney
Sydney, Australia
Rallison M. Dray, MD

VANTAGE
St. Vincent's Hospital
Bedford Park, Australia
Mark N. Humphries, MD

TECHNICAL UNIVERSITY OF MINNESOTA
Minneapolis, Minnesota, USA
Robert J. Kuzel, MD

TUNISIA
Hospital Aziza Othmana
Tunis, Tunisia
Balkis Meddeb, MD

TURKEY
Ankara University School of Medicine Hospital
Ankara, Turkey
Osman Ilhan, MD

UKRAINE
Research Center for Radiation Medicine
Kiev, Ukraine
Dimity Bazyka, MD

UNITED KINGDOM
Aberdeen Royal Infirmary
Aberdeen University School of Medicine
Foresterhill, Aberdeen, Scotland
Dominic Culligan, MD

Cambridge University Hospitals
Cambridge, United Kingdom
Alan J. Warren, MD, PhD

Christie NHS Foundation Trust
Manchester, United Kingdom
Mike Dennis, MD/Dan Wiseman, MD

King’s College London & King’s College Hospital
London, United Kingdom
Ghulam J. Mufti, DM, FRCP, FRCPath

Queen Elizabeth Hospital
University Hospital Birmingham NHS Trust
Birmingham, United Kingdom
Paresh Vyas, MD

Radcliffe Hospitals & University of Oxford
Oxford, United Kingdom
Jonathan Kell, MD

University Hospital Southampton
Southampton, Hampshire, UK
Christopher Dalley, MD

University of Wales Cardiff
Cardiff, Wales
Jonathan Kell, MD

VIETNAM
National Institute of Hematology and Blood Transfusion
Hanoi, Vietnam
Khanh Quoc Bach, MD, PhD
WE NEED YOU

JOIN THE FOUNDATION AS A MEMBER*

- You are part of the solution to change MDS outcomes. Your membership fee helps support global physician and patient educational initiatives, and helps to empower patients with courage and hope.
- Updates on the status of our Global Centers of Excellence and their live patient and family forum events that allow for more rapid dissemination of new research and treatment developments.
- Information on the latest clinical trials to potentially share or participate in.
- Access to MDS awareness materials to share with family and friends.
- Opportunities to participate in or host support group events with your friends and community.
- Receive two printed issues of The MDS News, which includes the latest on MDS research as well as inspiring patient and caregiver stories.

DONATE TO SUPPORT OUR MISSION*

- All donations are tax-deductible. Thank you in advance for your support!

AMAZON SMILE

- When you shop with Amazon Smile, Amazon will donate 0.5% of the price of an eligible purchase to the MDS Foundation. All you have to do is select Myelodysplastic Syndromes Foundation as your charity of choice.

VOLUNTEER*

- Volunteers are vital to our mission.

*PLEASE VISIT https://www.mds-foundation.org to discover how can you join, donate and volunteer
JOIN THE MDS FOUNDATION

THINKING OF JOINING THE MDS FOUNDATION AS A PROFESSIONAL MEMBER OR CHANGING THE FUTURE OF MDS MEMBER?

To join the MDS Foundation and help us fulfill our mission of moving closer to a cure for MDS, please visit our website at http://www.mds-foundation.org/professional-annual-membership-application.

CURRENT PROFESSIONAL MEMBERS

UNITED STATES: Aref Al-Kali, MD • Steven Allen, MD • Kimo Bachiaashvili, MD • Maria Baer, MD • Asad Bashay, MD, PhD • Rafael Bejar, MD, PhD • John Bennett, MD • Emmanuel Besa, MD • Kelly Bolton, MD, PhD • Andrew M. Brunner, MD • Victor Chang, MD, FACP • Alden Chesney, MD • Christopher Cogle, MD • Robert Collins, Jr., MD, FACP • Seth J. Corey, MD • Larry Crye, MD • Peter T. Curtis, MD • Magdalena Czader, MD, PhD • Carlos de Castro, MD • Matthew De Silva • H. Joachim Deeg, MD • Amy E. DeZern, MD, MHS • John DiPersio, MD, PhD • Erika Eksioglu PhD, MS • Salman Fazal, MD • Maria Figueroa, MD • James Foran MD, FRCPC • Stephen Forman, MD • Matthew Foster, MD • Steven Fruchtman, MD • Alejandro Garcia-Hernandez, MD • Guillerma Garcia-Manero, MD • Stuart Goldberg, MD • Timothy Graubert, MD • Peter Greenberg, MD • Elizabeth Griffiths, MD • Zartash Gul, MD • Gregory Hale, MD • Michel Hoessly, MD • Aaron Hoskins, PhD • Ishmael Jaiesimi, MD • Brian A. Jonas, MD, PhD • Mark Juckett, MD • Hagop Kantarjian, MD, PhD • Michael Keng, MD • Jeffery Klco, MD • Virginia M. Klimek, MD • Rami Komrokji, MD • Amelia Langston, MD • Richard Larson, MD • Jane Liesveld, MD • Mark Litzow, MD • Selina Luger, MD • Roger Lyons, MD, FACP • Philip McCarthy, MD • Stephen Medlin, DO • Kenneth Meehan, MD • Clelie Meloncon, MD • Raul R. Mena, MD • Melissa Mendez • Sanjay Mohan, MD • Lynn Moscinski, MD • Stephen Nimer, MD • Casey O’Connell, MD • Margaret R. O’Donnell, MD • Daniel Polleyea, MD, MS • Nagesh Rao, PhD, FACMG • Anastasios Raptis, MD • Azra Razza, MD • Brandi Reeves, MD • James M. Rossetti, MD • David Salman, MD • Srinivasa Sanikommu, MD, FACP • Marianne Sanguaguida, PhD • Michael Savona, MD, FACP • Hamid Sayar, MD • Dale Schaar, MD, PhD • Gary Schiller, MD • Richard K. Shaddock, MD • Paul Shami, MD • Jamile Shammo, FACP, FACP • Akiko Shimamura, MD, PhD • Barry Skikne, MD, FACP, FCP(SA) • Kellie Sprague, MD • Lisa Sprott, MSW • David Steensma, MD • Sandra Swantek, MD • Sachdev Thomas, MD • James Thompson, MD • Swapna Thota, MD • Zuzana Tothova, MD, PhD • Thu Le Trinh, MD • Amit Verma, MD • Alison Walker MD, MPH • Erica Warlick, MD • Cecilia Yi, MD • Amer Zeidan, MD

OUTSIDE OF THE UNITED STATES: Sergio Amadori, MD • Stefan Balabanov, MD • Indira Barbosa, BMA • Mariëlle Beckers, MD, PhD • Ann-Charlotte Björklund • Nicolas Bonadies, MD • Gesine Bug, MD • Jaroslav Cermak, MD, PhD • Suring Chen, MD, PhD • June-Won Cheong, MD • Michel Delforge, MD, PhD • Matteo Della Porta, MD • Maria Diez-Campelo, MD, PhD • Kalman Filanovsky, MD • Arnold Ganser, MD • Ulrich Germing, MD • Katharina Gotze, MD, PhD • Kirsten Grønbæk, Professor, MD • Emmanuel Gyan, MD, PhD • Detlef Haase, MD, PhD • Torsten Haferlach, MD • Stefa Heinrichs, PhD • Eva Hellstrom-Lindberg, MD, PhD • Irachmiel Huber, MD • Monika Jansson • Jonathan Kell, MD • Melita Kenealy, MD • Wolfgang Kern, MD, Professor • Anjum Khan, MD • Sally Killick, MD • Lars Kjeldsen, MD • Nicolaus Kroeger, MD, PhD • Saskia Langemeijer, MD, PhD • Heath Leitch, MD, PhD • Xiao Li, MD • Krzysztof Madry, MD, PhD • Tomoya Maeda, MD, PhD • Ulrich Maliknecht, MD, PhD • Inga Mandac Rogulj, MD • Markus Manz, MD • Claus Marcher, MD • Yasushi Miyazaki, MD • Teresa Mortora Blanco, PhD • Charlotte Niemeyer, MD • Kiyoyuki Ogata, MD, PhD, FACP • Stefani Parmentier, MD • Michael Pfeilstöcker, MD • Uwe Platzbecker, MD • Klas Raaschou-Jensen, MD • Markus Radsak, MD, PhD • Fernando Ramos, MD, PhD, MPH • Kevin Rouault-Pierre, PhD • Alicia Rovo, MD • Aleksandar Savic, Professor, MD • Mary Lynn Savoie, MD • John Seymour, MD • Lee-Yung Shih, MD • Jake Shortt, MD • Katja Sockel, MD • Reinhard Stauder, MD • Arigis Symeonidis, MD • Akifumi Takaori-Kondo, MD, PhD • Hwei-Fang Tien, MD, PhD • David Valcárcel, MD, PhD • Norbert Vey, MD • Athina Nora Viniou, MD, PhD • Despoina Violidaki, MD • Sara von Bahr Grebäck, PhD • Maria Teresa Voso, MD • Alan Warren, MD, PhD • Zhijian Xiao, MD • Yumi (Yamamoto) Ogata, BA • Karen Yee, MD • Yataro Yoshida, MD

CURRENT CHANGING THE FUTURE OF MDS MEMBERS: Camille Abboud, MD • Andrew Adams • Aref Al-Kali, MD • Kimo Bachiaashvili, MD • Barbara Bartlett • Mariëlle Beckers, MD, PhD • George Benson • Robert Bills • David Carden • Victor Chang, MD, FACP • Cheryl Coleman • Renee Conrad • Laurence Cove and Ann Brody Cove • Magdalena Czader, MD, PhD • John Soper, PhD, DABCC • Mark and Martha De Noble • James and Josephine Diedrich • Sally Ferguson • Lewis Flock • Steven Fruchtman, MD • Roman Suarez Garcia • David Galli • Andrew Glasgow • Stuart L. Goldberg, MD • Janice Gottlieb • Lee Harris • Theron and Brooke Hatch • Robert J. Heiss • Michel Hoessly, MD • Michael Hollandier • Lou and Kathy Jorge • Diane Jordan • Mark B. Juckett, MD • Jeffery Klco, MD • Marilee Korsinen • Marti Lawrence-Grant • Cathy Layton • Connie Lee Frederic and Kathleen Leverenz • James Lewin • G Malcolm Louden • Gene Lynes • Joe Maloney • David Mandell • Phyllis Mandell • Daniel McCormick • Robert McElveen • Julia McGuire • Milt Miller • Joseph O. Moore, MD • Yumi (Yamamoto) Ogata, BA • James Phillips • Katherine Radosh, MD • Brandi Reeves, MD • Harvey P. Root • Lorne Ruby • Walt Smith • John Stassenko • Joseph Strothers • Richard Sturm • Sandra Swantek, MD • Sachdev Thomas, MD • Swapna Thota, MD • Theresa Tinto • Janet B. Warfield • Stephen Francis Weber • Michael Weiner • Leon Weiss • JoEllen White • Kenan White • Leonard Yool
2020 PATIENT FORUMS

MARK YOUR CALENDAR FOR THE LOCATION NEAREST YOU!

PATEINT FORUMS 2020

FEBRUARY 1
Birmingham, AL

FEBRUARY 22
Houston, TX

MARCH 6
Tel Aviv, Israel

JUNE 27
Madison, WI

JULY 25
Chicago, IL

AUGUST 8
Palo Alto, CA

AUGUST 29
Denver, CO

SEPTEMBER 12
New York, NY

SEPTEMBER 26
Chapel Hill, NC

OCTOBER 30
Omaha, NE

NOVEMBER 7
Tampa, FL

DON’T MISS OUT ON THESE INFORMATIVE, FREE EVENTS

REGISTRATION IS REQUIRED

Register online at https://www.mds-foundation.org/patient-and-family-forums.

To register by phone or for any questions, call or email Janice Butchko at 1-800-637-0839 Ext. 212; jbutchko@mds-foundation.org

LEARN MORE AT:
www.mds-foundation.org/patient-and-family-forums

Many patients and caregivers have never met another person diagnosed with MDS until they connected with them at one of our forums. If you’ve never attended one, you won’t want to miss this opportunity to meet others and to learn more about MDS, current treatments, and emerging therapies from leading experts. Not only will you find answers, support and hope for MDS but you will learn tips and strategies for patients and caregivers LIVING with MDS.

PLEASE MAKE SURE TO REGULARLY CHECK OUR WEBSITE FOR MEETINGS TAKING PLACE IN A CITY NEAR YOU!
U.S. FDA APPROVES REBLOZYL® (LUSPATERCEPT-AAMT), THE FIRST AND ONLY ERYTHROID MATURATION AGENT, TO TREAT ANEMIA IN ADULTS WITH LOWER-RISK MDS

PRINCETON, NJ & CAMBRIDGE, MA, APRIL 3, 2020 — The FDA approval marks the second indication for Reblozyl and the first new treatment option in over a decade for patients with MDS who require red blood cell (RBC) transfusions and have failed an erythropoiesis-stimulating agent.

Reblozyl regulates late-stage RBC maturation to relieve patients from the burden of regular RBC transfusions.

Bristol Myers Squibb (NYSE: BMY) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced the U.S. Food and Drug Administration (FDA) has approved Reblozyl® (luspatercept-aamt), the first and only erythroid maturation agent (EMA), for the treatment of anemia failing an erythropoiesis-stimulating agent and requiring 2 or more red blood cell (RBC) units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). Reblozyl is not indicated for use as a substitute for ESA therapy or were ESA naïve and unlikely to respond due to endogenous serum erythropoietin ≥200 U/L, and had no prior treatment with disease modifying agents.

The FDA approval in MDS is based on results from the pivotal Phase 3 MEDALIST trial and marks the second indication for Reblozyl, which received its first approval in November 2019 for the treatment of anemia in adults with beta thalassemia who require regular RBC transfusions.1

“We’re excited that Reblozyl has been approved to help even more patients in need of treatment options,” said Habib Dable, President and Chief Executive Officer, Acceleron. “We are enormously grateful to the patients, families and caregivers who participated in and supported the Reblozyl clinical trials, and to the researchers at Acceleron and beyond who, more than a decade ago, began this important quest to address patients’ chronic anemias.”

ABOUT MEDALIST

The approval of Reblozyl was based on the findings of MEDALIST, a Phase 3, randomized, double blind, placebo-controlled, multi-center study evaluating the efficacy and safety of Reblozyl in patients with IPSS-R-defined very low-, low- and intermediate-risk non-del(5q) myelodysplastic syndromes (MDS) with ring sideroblasts. All patients were red blood cell (RBC) transfusion-dependent and were either refractory or intolerant to prior erythropoiesis-stimulating agent (ESA) therapy or were ESA naïve and unlikely to respond due to endogenous serum erythropoietin ≥200 U/L, and had no prior treatment with disease modifying agents.

In the trial, a significantly greater proportion of patients receiving Reblozyl achieved independence from RBC transfusions for at least eight weeks during the first 24 weeks of the trial compared with those receiving placebo, meeting the study’s primary endpoint.2 Additionally, a significantly greater proportion of patients receiving Reblozyl vs. placebo achieved at least 12 weeks of independence from transfusions within the first 24 and 48 weeks of the study.2

The majority of treatment-emergent adverse events (TEAEs) in the trial were Grade 1–2. Grade 3 or 4 treatment-emergent adverse events were reported in 42.5% of patients who received Reblozyl and 44.7% of patients who received placebo. The most common (>10%) all-grade adverse reactions included fatigue, musculoskeletal pain, dizziness, diarrhea, dyspnea, nausea, hypersensitivity reactions, headache, and upper respiratory tract infection.2

Results from MEDALIST were published in the New England Journal of Medicine in January 2020.

ABOUT REBLOZYL®

Reblozyl, the first and only erythroid maturation agent, promotes late-stage red blood cell maturation in animal models.1 Bristol Myers Squibb and Acceleron are jointly developing Reblozyl as part of a global collaboration. Reblozyl is currently approved in the U.S. for the treatment of:

• anemia in adult patients with beta thalassemia who require regular red blood cell transfusions, and
• anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syn-
dromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).

Reblozyl is not indicated for use as a substitute for red blood cell transfusions in patients who require immediate correction of anemia.

**Indication**

REBLOZYL is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions

REBLOZYL is indicated for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)

REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.

**The program features:**

- Immediate access for patients who have lost their employment and health insurance;
- A simple, single point of entry;
- Streamlined enrollment process; and
- Vouchers to assist with continuity of care for several self-administered BMS medicines, for eligible patients

All Bristol Myers Squibb patient support programs, as well as, additional eligibility requirements, can be reached by calling (800) 721-8909 or by visiting BMS.com.

“The COVID-19 pandemic has created unprecedented financial challenges for patients and families, adding considerable new stress to the millions of Americans who have lost their jobs and health insurance,” said Giovanni Caforio, MD, chairman and chief executive officer, Bristol Myers Squibb. “As more patients face difficult decisions in their daily lives, it is important to continue their treatments.”

Bristol Myers Squibb’s Response to COVID-19

Bristol Myers Squibb recognizes this is a challenging time for everyone. The company will continue to take all necessary actions to promote public health and carry out its mission of providing life-saving medicines to the patients who depend on us. Please visit BMS.com to learn more about our actions to date.

**COVID-19: IMMEDIATE RELIEF AVAILABLE**

**BRISTOL MYERS SQUIBB EXPANDS PATIENT SUPPORT PROGRAMS TO HELP NEWLY UNINSURED PATIENTS IN THE U.S.**

PRINCETON, NJ, APRIL 7, 2020 –

Bristol Myers Squibb (NYSE: BMY) today announced an expansion of its existing patient support programs to help eligible unemployed patients in the U.S. who have lost their health insurance due to the COVID-19 pandemic.

The expanded program offers access to any branded Bristol Myers Squibb medicine for free, including some of its most widely prescribed products, as well as those prescribed via telehealth services.

**ASTEX PHARMACEUTICALS ANNOUNCES U.S. FOOD AND DRUG ADMINISTRATION (FDA) ACCEPTANCE FOR REVIEW OF AN NDA FOR THE COMBINATION ORAL HYPOMETHYLATING AGENT CEDAZURIDINE AND DECITABINE (ASTX727 OR ORAL C-DEC), FOR THE TREATMENT OF MDS AND CMML**

PLEASANTON, CA, FEB 11, 2020 – Astex Pharmaceuticals announces U.S. Food and Drug Administration (FDA) acceptance for review of an NDA for the combination oral hypomethylating agent cedazuridine and decitabine (ASTX727 or oral C-DEC), for the treatment of MDS and CMML

- NDA is supported by data from the phase 3 ASCERTAIN study of oral C-DEC in adults with intermediate- and high-risk myelodysplastic syndromes (MDS) including chronic myelomonocytic leukemia (CMML)
- FDA designated the application for Priority Review
- Potential for oral C-DEC to become first approved orally administered hypomethylating agent for MDS and CMML in the U.S.

Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co., Ltd., based in Japan, today announced that the U.S. FDA has accepted for Priority Review its NDA for oral C-DEC (cedazuridine and decitabine) as a treatment for adults with previously untreated intermediate- and high-risk MDS including CMML. The NDA submission is based on data from the ASCERTAIN phase 3 study which evaluated the 5-day decitabine exposure equivalence of oral C-DEC and IV decitabine.

“We are very pleased that the FDA has accepted our NDA for Priority Review,” said Dr Mohammad Azab, MD, president & chief medical officer of Astex Pharmaceuticals, Inc. “Subject to FDA review and regulatory approval, oral C-DEC may offer a new option for patients with MDS and CMML that saves them the burden of 5-day IV infusions every month during their treatment period. We are grateful to all the patients, investigators and other healthcare providers, and partner research and manufacturing organizations, who contributed to the clinical development program of oral C-DEC.”

The FDA grants Priority Review to applications for drugs that, if approved, would provide significant improvements in
the safety and effectiveness of the treatment, diagnosis or prevention of serious conditions. The Priority Review designation means FDA’s goal is to take action on an NDA application within six months (compared to the ten months under standard review).

Oral C-DEC is an investigational compound and is not currently approved in any country.

Astex’s parent company, Otsuka Pharmaceutical Co., Ltd., and Taiho Pharmaceutical Co., Ltd. previously announced that, subject to regulatory approvals, commercialization of oral C-DEC in the U.S. and Canada will be conducted by Taiho Oncology, Inc. and Taiho Pharma Canada, Inc. respectively. Astex, Otsuka and Taiho are all members of the Otsuka group of companies.

ABOUT C-DEC (CEDAZURIDINE 100 MG AND DECITABINE 35 MG) FIXED-DOSE COMBINATION

C-DEC is a novel, orally administered fixed dose combination of cedazuridine, an inhibitor of cytidine deaminase, with the anticancer DNA hypomethylating agent, decitabine. By inhibiting cytidine deaminase in the gut and the liver, C-DEC is designed to allow for oral delivery of the approved DNA hypomethylating agent, decitabine, at exposures which emulate exposures achieved with the approved intravenous form of decitabine administered over 5 days.

C-DEC has been evaluated in a phase 1/2 pharmacokinetics-guided dose escalation and dose confirmation study in patients with MDS and CMML (see https://www.clinicaltrials.gov NCT02103478) and a pivotal phase 3 study (ASCERTAIN) (see https://www.clinicaltrials.gov NCT03306264) conducted at investigator sites in the US and Canada and designed to confirm the results from the phase 1/2 study. The phase 3 study is now being extended to include patients with acute myeloid leukemia (AML) unsuitable to receive intensive induction chemotherapy.

In September 2019 Astex announced that C-DEC had received orphan drug designation for the treatment of MDS and CMML from the U.S. FDA.

The concept of using cedazuridine to block the action of cytidine deaminase is also being evaluated in a low dose formulation of cedazuridine and decitabine for the treatment of lower risk MDS (see https://www.clinicaltrials.gov NCT03502668).

ABOUT THE PHASE 3 ASCERTAIN STUDY

The study was designed as a randomized crossover study comparing oral C-DEC (cedazuridine 100 mg and decitabine 35 mg fixed-dose combination tablet given once daily for 5 days on a 28-day cycle) to IV decitabine (20 mg/m² administered as a daily, 1-hour IV infusion for 5 days on a 28-day cycle) in the first 2 cycles with patients continuing to receive oral C-DEC from Cycle 3 onwards. The data from the ASCERTAIN study was presented at the American Society of Hematology (ASH) Meeting in Orlando, Florida in December 2019 by Dr. Guillermo Garcia-Manero, MD, professor and chief of section of myelodysplastic syndromes, Department of Leukemia at The University of Texas MD Anderson Cancer Center, on behalf of the study investigators. The data demonstrated that the ASCERTAIN study met the primary endpoint of total 5-Day decitabine Area-Under-The-Curve (AUC) equivalence of oral C-DEC and IV decitabine. Safety findings from the study were consistent with those anticipated with IV decitabine, with no significant differences in the incidence of most common adverse events between oral C-DEC and IV decitabine in the first 2 randomized cycles. The most common adverse events of any grade >20% regardless of causality in patients in the first 2 randomized cycles who received oral C-DEC were thrombocytopenia (43.8%), neutropenia (35.4%), anemia (36.9%), and fatigue (23.8%). The ASH presentation can be downloaded from the Astex website at https://astex.com/media-center/presentations-andpublications/ASTX727-ASCERTAIN-Presentation-ASH-December-2019.

REFERENCES

To order your FREE copy of our resources available in multiple languages, please visit our website: https://www.mds-foundation.org/material-order-form-4/
MY JOURNEY TO A HAPLOIDENTICAL STEM CELL TRANSPLANT

TOM HAYGOOD
Hendersonville, Tennessee

I have what?? Myelodysplastic Syndrome?? That’s how my journey began six years ago at age 62. It was the fall of 2013 when the common symptoms of MDS started. Fatigue and joint pain became a common occurrence in my everyday life. After a visit to my family doctor, blood tests were run and the results indicated some abnormalities. I was referred to a local hematologist who ordered additional blood tests along with a bone marrow biopsy and CT scan. With those results in hand, I was diagnosed with MDS. Since I’d never heard of the disease, the MDS Foundation and the Leukemia & Lymphoma Society were excellent resources to learn more about MDS. I also joined an MDS support group on Facebook.

I live in Hendersonville, Tennessee, a suburb of Nashville, and was fortunate that I was able to receive all my treatment close to home in Nashville. In January 2014, I was referred to Tennessee Oncology at the Sarah Cannon Center for Blood Cancer at Centennial Medical Center. The Center is named after patient Sarah Cannon who was better known as Minnie Pearl of the Grand Ole Opry! She offered the use of her given name and financial support to promote cancer research and patient education.

My subtype of MDS was RAEB. I was on “watch & wait” for 8 months. When my blood counts became lower and another bone marrow biopsy showed an increase in blasts, I began treatment with Vidaza in August 2014. I went 7 days a month, M-F and M-Tu and received 3 subcutaneous injections in my stomach. Other than irritation at the shot sites and fatigue, I had minimal side effects, but I did retire in September since my job required traveling and my immune system was very weak.

After 19 months of shots, I had a port implanted in March 2016 and began receiving Vidaza infusions on the same 7 day schedule. In October 2016, I walked my daughter down the aisle at her wedding in Denver! I changed to a 5 day schedule of infusions in January 2017.

In June 2017, after 32 rounds of Vidaza, my counts did not recover and a bone marrow biopsy indicated 12% blasts. I was referred to Dr. Carlos Bachier at the Blood and Marrow Transplant Clinic at Sarah Cannon Cancer Center. I was evaluated with a series of tests and determined to be a good candidate for a stem cell transplant. Since there was no donor match from the international registry and my siblings were not suitable donors due to health issues, the decision was made to have a haploidentical SCT. I have two daughters so they were both evaluated as potential donors. My younger daughter Lisa, 32, was chosen as my donor since she had never been pregnant, and my older daughter had given birth to our three awesome grandchildren.

I was admitted to the Immunosuppression Unit at Sarah Cannon Cancer Center on August 21, 2017, which was the date of the solar eclipse. That seemed appropriate since we anticipated some dark days ahead. I began an intense round of 7-3 induction chemo to prepare my immune system for my upcoming SCT. The chemo was administered thru a PICC line. My wife kept a daily journal and began a website for me on CaringBridge.org to keep our family and friends updated. I had severe mucositis from the chemo which made it difficult to eat. I knew I would eventually lose my hair, so I decided to shave my head one night. My wife was surprised the next morning to find a strange bald headed man in my room! On days when I felt good enough, I walked laps around the floor with a goal of 2 miles a day. My bone marrow biopsy showed no evidence of

Tom’s donor – his daughter, Lisa
disease, but I had to wait until my ANC count increased before I could be discharged. After 32 days in the hospital, I went home on Sept. 21 for 15 days. During that time, I had a Central Venous Catheter implanted for my upcoming SCT.

On October 6, 2017, I was readmitted to the hospital for 5 days of chemo and one Total Body Irradiation treatment prior to my SCT. Lisa arrived from Denver and began her series of Neupogen injections to stimulate stem cell growth. She received two shots in her stomach for 5 days. She did not have any side effects from the shots and even ran a 5K event one morning before coming to the hospital for her shots. She posted daily videos on Facebook to encourage others to register as donors on BetheMatch.org. On October 11, she had 580 million stem cells harvested in 7 hours of apheresis. Her only complaint was being bored during the procedure! I consider myself conservative, and it was the family joke that I would change after receiving her liberal stem cells! That didn’t happen. They were stem cells, not brain cells!

On October 12, 2017, with my family surrounding me, I had my SCT which took about 30 minutes. Afterwards, I was given another 3 days of chemo and began all the medications for transplant patients. On the 18th day after my transplant, my bone marrow biopsy showed no blasts! I became an impatient patient waiting for my counts to increase. Finally, after 25 days in the hospital, I was discharged on October 30. Since I live within 30-45 minutes of the hospital, I was thrilled that I was allowed to go home instead of staying in a facility near the hospital. It was a real treat to be home for Halloween. My bone marrow biopsy in November showed 100% donor cells and no blasts! I had lots of follow-up appointments and stayed at home most of that winter. Since that time, I have had regular follow-up visits and bone marrow biopsies. I have had some minor skin and lung GVHD and neuropathy in my feet, but no other complications.

I celebrated my 2nd birthday last October, and I enjoy playing golf with friends 3-4 days a week! I am fortunate that my haploidentical transplant was successful. I have been blessed with great doctors and nurses, supportive family and friends, and lots of answered prayers in the past six years, and I am thankful for my wonderful wife Gail who has been by my side in sickness and health for 47 years. I hope my journey will be encouraging to others diagnosed with MDS.
LOOKING FORWARD

JANET B. WARFIELD, MSN
Nashville, Tennessee

My journey with MDS began in March of 2014. My husband, Bill and I flew to San Diego and then took a beautiful drive through the San Bernardino mountains to Indian Wells. We had tickets to the Indian Wells professional tennis tournament. I was especially excited because we were going to see Rafa Nadal play. We arrived on a Friday night exhausted from a long day of travel. I remember not feeling very well but went to dinner and then bed hoping a good nights sleep was all I needed. Bill was up bright and early the next morning. Although we had tickets to see Rafa play that night, Bill went in search of tickets for the day sessions. I realized after he left the hotel room that I literally could not get out of bed. I googled altitude sickness as I was self diagnosing the sudden onset of my fatigue. I slept all day and forced myself up and on the bus to the stadium to meet Bill for the night session to see Rafa play. This was a bucket list moment for me and I wasn’t going to miss it.

Upon our return to Nashville, I had an appointment for my annual physical with my general practitioner. I told him about my episode of fatigue while on vacation. He said everything checked out but he would be in touch with lab results from bloodwork. A week or so later I received a letter that my blood was showing signs of anemia and I needed to return for more specific testing for vitamin deficiencies. A few days later, I received a call that changed my life. He said I didn’t have a vitamin deficiency and that he was referring me to a blood specialist for further testing. I googled the specialist and my heart almost stopped when I saw he was sending me to an oncologist.

My oncologist couldn’t have been nicer or more honest. After additional blood work, a PET scan and a bone marrow biopsy I was diagnosed with primary MDS. The fear that I experienced at that moment still resonates with me today. I learned that I was young at age 58 to have this rare form of blood cancer. My SF3B1 mutation with ringed sideroblasts put me in the low risk category of MDS which meant that I was not at risk for developing leukemia. It also meant there were currently no treatment options. So I left the oncologist that day in May of 2014 with a diagnosis of bone marrow cancer with a plan to return every 8 weeks for bloodwork. As long as my numbers stayed within a certain range, I would not qualify for any of the available medical treatment protocols for MDS which was a good thing. The best advice he could give me was to “just go live my life”.

My life at that time was very busy and blessed. I was a wife to a very special man, mother to a beautiful 24 yr old daughter, Carly, and two precious King Charles Spaniels as well as a daughter to two wonderful aging parents. I was CFO of a nonprofit called Mending Hearts, Inc. which is a residential treatment facility for indigent women. I also had been a competitive tennis player for 20 years.

I needed to learn more about this disease. I found the MDS Foundation online. I requested information and they sent me the Building Blocks of Hope, which I still use as a resource today. I have attended three of their patient forums and participated in both Boston walks. The staff at the MDS Foundation is a group of incredible women who have given me support and hope and I’m so very grateful to each of them. I’ve tried volunteering for MDS research studies but so far I’ve not qualified since I’ve not had any type of treatment. Instead of focusing on my illness, I’ve been trying to focus on educating myself and connecting with others in the MDS community. I’m so excited that Nashville will be hosting a MDS Awareness Walk in the fall of this year! It’s so important that we bring awareness to this devastating disease.

I also searched out alternative treatment options in an attempt to improve my health. I began seeing a doctor of naturopathy in January 2015. I still see her twice a month for lymphatic massage, O2 therapy and bemer mat sessions. She advises me on nutritional supplements that address my suppressed immune system. She also encourages me to eat healthier. I have added Pilates and weight training to my exercise regimen. Are any of these things actually helping my MDS symptoms? I can say that when I adhere to the regimen I have more energy. I have succumbed to just one or two infections a year and my blood levels have remained about the same since 2014. I believe that being
proactive about my health has given me a feeling of empowerment and it's been a way for me to actively manage my disease.

I have tried not to change my life dramatically following my diagnosis. I experience some fatigue most days and shortness of breath when walking if the terrain is not flat. I've found that I'm more susceptible to infections. I've gradually learned what I need to do to manage these symptoms. I did quit my job in the summer of 2014. My parents' health was beginning to fail and I wanted to be able to devote more of my time to them. My sweet mom passed in 2016. I miss her so much. My dad celebrated 93 years in October of last year. He has multiple health issues and is now living in a skilled nursing care facility but has the greatest attitude and I treasure every minute I get to spend with him. I am still playing competitive tennis, although not at the same level I played when first diagnosed. My visits to the oncologist are still just every 8 weeks for bloodwork and for that I'm most grateful.

My husband and daughter have been my rock and they are the reason that each day is a blessing for me. They encourage me to do all that I can but are so supportive when I need to slow down. MDS has had a positive effect on how our family chooses to live our daily lives. MDS was a huge wake up call that life is short and each day is a gift not to be taken for granted. I keep my bucket list close by and am constantly updating it. It keeps me hopeful and focused on looking forward. I still experience the fear that comes with having MDS, but that fear does not keep me from following my doctors orders to "go live my life". I realize I'm one of the luckier ones with a MDS diagnosis and that my prognosis is better than most people in the MDS community.
CHASING THE CARROT...

JILL WHITNEY
Redding, California

My journey with MDS (Myelodysplastic Syndromes) began in December 2007. After playing volleyball with my youngest daughter, I noticed that my forearms were badly bruised. This along with frequent headaches and fatigue prompted me to schedule an appointment for a physical. Little did I know our lives were about to change forever.

We were getting ready to depart on a cruise to Cabo San Lucas, Mexico to celebrate my in-laws’ 50th anniversary, but my local hematologist wouldn’t allow me to go until a bone marrow biopsy was done. At first, he suspected a vitamin B-12 deficiency. B-12 injections helped for a short time, but then my counts slowly began to decline, especially my platelets.

After six long months and numerous tests, I was finally referred to a hematologist at Stanford University Hospital in Palo Alto, California. My husband and I were told that I had MDS and a bone marrow transplant was the only cure. It was a lot for us to absorb. We somehow managed to hold it together through the appointment, but as soon as we got to our car, we held each other and cried. I was only 47. I couldn’t help but wonder if I would ever get to see our youngest daughter graduate from high school or even hold our first grandchild. I couldn’t bear the thought of leaving my family.

At the time, I was considered intermediate to high risk and my only sibling was my half-brother, Jim, so a search began through the National Marrow Donor Program. I continued working until we received word that four possible donor matches were found. Our youngest daughter was 14 and Stanford was four hours away from our home in Redding, California. We had a lot of preparation to do before the transplant, so I left my job as a registered dental assistant and my counts stabilized. We were able to put everything on hold for nearly a year and a half. During this time, our first granddaughter arrived.

I was scheduled to begin the conditioning for the transplant (cytoxin and busulfan) on May 4, 2010, but due to respiratory symptoms, it was delayed. Having to wait an additional two weeks was disappointing, although I know it was for my own safety. I was admitted to the bone marrow transplant unit at Stanford on May 17th and on May 25th I received the life-saving stem cells from a 47-year old male, German donor. I had a few setbacks that kept me in isolation longer than expected. I spent four days in the ICU due to an E. Coli blood infection and then contracted BK virus. I watched the days pass by on a giant calendar that showed my daily blood counts and notes of inspiration from the nurses. I had hoped to be discharged in time to spend the 4th of July with my husband, but that day passed.

One good thing that came out of my late release, was getting to meet Alex Smith, quarterback for the San Francisco 49er’s and several other team members when they paid a surprise visit to the BMT Unit.

On day +44, I was released to an apartment we had rented nearby. At first, my husband took me to the infusion treatment area daily for blood draws and to receive needed transfusions. When he returned to work, I was moved to my parents’ home, about 30 minutes from Stanford. Then, I came down with CMV virus and had to remain close to Stanford for an additional 6 weeks. I finally returned to my home in Redding at the end of September 2010.

Eight months following the transplant, we were told that I had relapsed and a second transplant wasn’t an option due to congestive heart failure. I was given a prognosis of a few weeks to possibly a few years, if I began treatment. I had not even recovered from the transplant and was now facing chemotherapy. We were devastated. Desperate for help, my husband and I attended an MDS Foundation conference in San Francisco, where Jason Gotlib, MD was a guest
speaker. My husband approached him after the event and asked if he would accept me as a patient. I started receiving Vidaza (azacitadine) via port-a-cath in February 2011, but my counts had a hard time recovering. For the first few months, I was so sick that I needed help getting out of bed. I was nauseated and had no appetite. My family begged me to eat. At times, I wanted to give up.

I gave myself insulin and Neupogen injections and had to take numerous medications. For 18 months, I required frequent transfusions until a bad reaction caused me to break out in huge welts all over my body. From then on, the platelets had to be HLA matched and packed. Luckily, things started turning around. Our second granddaughter arrived in February 2012. I pushed myself to get better so that I could be present at our youngest daughter’s high school graduation and our middle daughter’s wedding a few months later. My family kept dangling these carrots out in front of me so that I would keep fighting.

I recently completed my 72nd cycle of Vidaza (azacitadine) and it has now been nine years since my relapse. On May 25, 2020, I will CELLebrate the tenth anniversary of my stem cell transplant (re-birthday). I tolerate chemotherapy pretty well now and take medication to mitigate the side effects. When it is no longer effective, we will have to look at other options, but I am so fortunate to have made it this far.

Unable to work due to ongoing treatments and fluctuating blood counts, I searched for a way to give back and keep my mind off my illness. I volunteered in the Cancer Resource Center at our local hospital for a while and then I came up with an idea where I could work from home. I started Signs of Hope and I have now created over a hundred inspirational signs to help others going through a difficult time. Some I have donated to our local hospital and to the oncology center where I receive treatment. I also started an MDS support group in my community with the assistance of the MDS Foundation.

I am forever grateful for the incredible gift of life from my donor, Michael, and for the care I have received from the outstanding doctors, nurses and support staff at Mercy Medical Center and Stanford, including Dr. Gotlib and transplant specialist, Dr. Wen-Kai Weng. I also would not be here today without my amazing family. Their love and encouragement is what has kept me pushing forward. My husband, Roger, has been my rock. I can’t count how many times he has driven me back and forth to Stanford or how many hours he has spent sitting with me in doctor’s offices. He cooked, cleaned and took care of our youngest daughter and me. I know it wasn’t an easy job. My parents, Rick and Lynne, and our eldest daughter, Amber, were my caregivers when my husband was working and daughters, Candace and Kaylynn, helped in any way they could. We also had the support of extended family and friends.

I’m not done living yet. I have too much to look forward to. My husband and I both turn 60 this year and in 2021 we will celebrate our 40th anniversary. I now have five beautiful grandchildren that keep me on my toes and I want to be around to watch them grow up. I have to keep chasing those carrots.
I would like to take this opportunity to tell you about a very special man that was in my life, he was my hero, he was my father. My father was born and raised in Los Angeles by his parents, two Italian immigrants from Italy. My father always wanted to be a firefighter with the Los Angeles City Fire Department. He was a very special man, and always had a desire to help his fellow man. Then World War II broke out so my father enlisted in the United States Navy. He served his country well as a machinist mate 2nd class aboard the USS Bliss (a troop transport). After the war, my father worked odd jobs until he was able to live out his dream of becoming a Los Angeles City Firefighter. Whatever job my father held, he put his heart and soul into it and did the best job that he could. He lived, breathed and ate the Los Angeles City Fire Department. He made many friends on the job and truly believed in “The Brotherhood” that firemen have. While on the job, he worked side jobs such as he was the safety officer when they dynamited Chavez Ravine and built what is now Dodger Stadium. The fire department was also responsible to have a fireman as a safety officer on movie locations and my father worked with the likes of John Wayne and Kirk Douglas. He loved his job. He remained on the Los Angeles City Fire Department for 25 years until his retirement in 1977. It wasn’t the job that made him retire, he was tired of all the traffic and smog that comes with living in Los Angeles. It was his time to relax and enjoy his retirement in Carlsbad, CA. He still stayed connected with his “firemen” buddies and would meet monthly with a group of them for breakfast and talk about the job. Once a fireman always a fireman.

Sometime around 2009, I went to visit my father in the hospital and overheard he and my mother speaking about seeking an appointment with an oncologist. The word “oncologist” stuck in my head and I asked him why he had to see an oncologist. My father did not lie very well and he told me “Oh, he does other things besides oncology”. I’m thinking to myself “no way”. After visiting with my father, I went home and immediately called my brother and told him what dad had said. I told my brother that something wasn’t right. After my father got out of the hospital my brother and I went over to his house and confronted him about what I heard him say in the hospital. It was then that he told us that he had MDS and had had it for 4 years already. We asked him why he didn’t tell us that he had it and he said “I didn’t want people to feel sorry for me”.

I started finding out as much as I could about MDS and that is when I found out that there were no MDS support groups in Southern California. I wanted my father to get as much information about the disease and by starting the first Southern California MDS Support Group in Oceanside, I was able to get a lot of great speakers who had some valuable information. I not only wanted to help my father but we had a great bunch of people in our support group who became “my family” and I wanted to help them as well. I couldn’t stress enough for the members (including my father) to go to an MDS specialist not just a general hematologist or oncologist. My father had been going to a general oncologist who basically just gave my father over 80 blood transfusions, which gave him iron overload. My brother and I took our dad to the City of Hope and to Moores Cancer Center for second opinions, but by the time we knew of my dad’s disease and were able to get him to these two facilities there was nothing more they could do for him.

My father got progressively worse and his quality of life was nothing. He decided he had had enough and he refused any more treatment.

Then on November 1, 2012, my hero, this man that had been my source of strength for so many years, was taken away from me by this ugly disease, MDS. While running the support group in Oceanside, I organized a blood drive with the San Diego Blood Bank and we had a huge success in getting a lot of blood donated and it was marked to be used only for MDS patients. My only regret is that my father passed away two weeks before we had the blood drive so he could not see the amount of people who so generously donated their blood to help people they did not even know. I was overwhelmed by the amount of Marines that drove by the donation site, saw the sign and stopped to donate blood. It kind of came full circle. Here were men defending our country (as my father did during WWII) and now donating blood to help people they didn’t know (like my father helped people he didn’t know by putting out fires in Los Angeles). I contacted the Oceanside Fire Department and shared my father’s story and that he would be so proud if the fire department participated in the blood drive in some way. They very generously sent a vintage fire truck manned with firefighters to the blood donation site, and stayed for the entire time speaking with everyone and letting them take a look at the fire truck. I was very touched by their generosity.

I am now in charge of a new MDS Support Group and we meet at St. Patrick Catholic Church in Carlsbad, CA. I also planned another blood drive on November 16, 2019 and invited the Carlsbad Fire Department. The public is grateful for all that firefighters do and it drew a lot of people to donate for those deserving people who need it to live. It was icing on the cake as some Carlsbad firemen also came and donated blood in honor of their fellow firefighter, my father (Remo Tersolo), my HERO. The Brotherhood...
OUR CAREGIVER STORIES

A LITTLE DIFFERENT STORY

LORI NELSON
Burnsville, Minnesota

Two years ago, my husband Curt (74 years old) was told that he had MDS. What was this new chapter in our lives? Did we know anyone in our circle of friends who we could identify with? Did anyone have knowledge or tips for us?

Turning to the internet, I found the MDS Foundation and reached out to them. Wonderful material resources soon arrived in the mail; however, we came to find out that there weren’t any MDS Support Groups in our region of Minnesota. The MDS Foundation, Patient Liaison, Audrey Hassan, suggested “YOU could start one.” ME? Maybe we could! What would we need to facilitate a meeting? Audrey suggested that we first find a meeting place and that the MDS Foundation could help provide startup funds that could be used to buy refreshments. We placed a few meeting notices in the local newspapers, the foundation posted information about our group on their website and on their social media platforms and sent us a box of great materials to distribute, and I bought cookies. And yes…they came.

Our group of 15 meets 4 times a year at the library community room. We share treatments, favorite medical teams, and tips to endure transfusions and treatments. One thing we have in common is that we know no one, outside of the support group, who has MDS. It can be a lonely walk with MDS so it’s so important to know that you are NOT alone.

At this time, my husband’s blood counts are high enough to not require any treatment. We are privileged to know this wonderful group of caring and supportive people.

MINNESOTA MDS SUPPORT GROUP:
The Minnesota MDS Patient Support Group meets quarterly 3:30 PM at Burnhaven Library Main Meeting Room, 1101 County Road 42 W, Burnsville, MN 55306 (corner of Burnhaven and Co. 42). Contact Group Leader, Lori Nelson at 952-892-3659 or email curtlori45@yahoo.com for upcoming events.

NEW MDS SUPPORT GROUP TOOLKIT NOW AVAILABLE

ONE OF MDSF’S GOALS IS TO EXPAND THE NUMBER OF SUPPORT GROUPS WORLDWIDE

We are always on the lookout for people who are willing to start a group, offer some support in their area, and widen our support services to include more individuals affected by MDS.

We want to make it as easy as possible for volunteers to create and run support groups to ensure they can provide continuous comfort to those utilizing them.

We have created a Support Group Leader Toolkit that will provide guidance on how to run the group, suggestions for discussion topics, useful tools like sample letters and forms, and various other resources to help the meetings run smoothly.

If you live in a state without an MDS Support Group just buy some cookies and find a community space…and they will come!!!

A LITTLE DIFFERENT STORY

LORI NELSON
Burnsville, Minnesota

Two years ago, my husband Curt (74 years old) was told that he had MDS. What was this new chapter in our lives?? Did we know anyone in our circle of friends who we could identify with? Did anyone have knowledge or tips for us?

Turning to the internet, I found the MDS Foundation and reached out to them. Wonderful material resources soon arrived in the mail; however, we came to find out that there weren’t any MDS Support Groups in our region of Minnesota. The MDS Foundation, Patient Liaison, Audrey Hassan, suggested “YOU could start one.” ME? Maybe we could! What would we need to facilitate a meeting? Audrey suggested that we first find a meeting place and that the MDS Foundation could help provide startup funds that could be used to buy refreshments. We placed a few meeting notices in the local newspapers, the foundation posted information about our group on their website and on their social media platforms and sent us a box of great materials to distribute, and I bought cookies. And yes…they came.

Our group of 15 meets 4 times a year at the library community room. We share treatments, favorite medical teams, and tips to endure transfusions and treatments. One thing we have in common is that we know no one, outside of the support group, who has MDS. It can be a lonely walk with MDS so it’s so important to know that you are NOT alone.

At this time, my husband’s blood counts are high enough to not require any treatment. We are privileged to know this wonderful group of caring and supportive people.

MINNESOTA MDS SUPPORT GROUP:
The Minnesota MDS Patient Support Group meets quarterly 3:30 PM at Burnhaven Library Main Meeting Room, 1101 County Road 42 W, Burnsville, MN 55306 (corner of Burnhaven and Co. 42). Contact Group Leader, Lori Nelson at 952-892-3659 or email curtlori45@yahoo.com for upcoming events.

NEW MDS SUPPORT GROUP TOOLKIT NOW AVAILABLE

ONE OF MDSF’S GOALS IS TO EXPAND THE NUMBER OF SUPPORT GROUPS WORLDWIDE

We are always on the lookout for people who are willing to start a group, offer some support in their area, and widen our support services to include more individuals affected by MDS.

We want to make it as easy as possible for volunteers to create and run support groups to ensure they can provide continuous comfort to those utilizing them.

We have created a Support Group Leader Toolkit that will provide guidance on how to run the group, suggestions for discussion topics, useful tools like sample letters and forms, and various other resources to help the meetings run smoothly.

If you are interested in starting a support group of your own, please contact Audrey Hassan at 1-800-MDS-0839 Ext. 210 or email ahassan@mds-foundation.org.
YOU AND AML: AN ANIMATED PATIENT’S GUIDE TO ACUTE MYELOID LEUKEMIA

This resource is intended for patients with acute myeloid leukemia (AML). You will find expert advice about AML, AML with myelodysplasia-related changes (AML-MRC) and treatment-related AML (tAML) to help you discuss key issues with your healthcare provider and make important decisions related to management and treatment.

"YOU AND AML" CONTAINS 4 LEARNING MODULES:
• Understanding AML
• Understanding AML-MRC and tAML
• Diagnosing AML, AML-MRC and tAML
• Treatment of AML

Each module contains easy-to-understand animations with audio narration, video explanations by AML experts, patient interviews, and illustrated slide shows.

You and AML
An Animated Patient’s Guide to Acute Myeloid Leukemia
www.YouAndAML.com

SURVIVOR

VALERIE FONS
Washington Island, Wisconsin

God on high, hear my prayer,
In my need, you have always been there.
He is young, he’s afraid, let him rest,
heaven blest.
Bring him peace. Bring him joy.
He is young. He is only a boy.
Let him live.
You can take. You can give. Let him be.
Bring Him Home, Les Miserables

Surrounded by the Atlantic Ocean and the Caribbean Sea is the Island of Hispaniola and the town of Puerto Plata. When my canoeing partner and I landed at this seaport town, we had already traveled nine thousand miles in our solo canoes from the Arctic Ocean enroute to Cape Horn, Chile. I sought the cool peace of sanctuary and walked down a street paved in dirt, bordered by open sewer ditches to a stone building with the sign of a cross.

On the steps of the St. Philip Cathedral, women are holding babies. Lame, and diseased, with bleeding sores on his leg, a man sat on the steps with his open palm propped on his bent knee.
Small children stand with distended bellies, not playing but quiet, watching. All have eyes of longing. Each hand is outstretched in need. I walk between the people, through the open wooden doors, onto the marble aisle, making my way to the altar where I kneel and thank God for our progress to this island.

The journey has not been easy. There were landslides on the Mackenzie River, Northwest Territories, Canada. My partner broke ribs near Ft. Simpson. Inebriated locals chased us at Red Dog. We were frozen to the seats of our canoes in Keweenaw Bay, spooked by alligators in Florida, and paddled nonstop for fifty hours on an open water crossing in the Caribbean. There were ten thousand miles of water still ahead. In the cathedral at Puerto Plata, I breathed deeply. The furrow on my brow that was becoming a characteristic facial expression began to relax, for I had escaped the noon heat and felt that at this moment there was no threat.

When I stood from the prayer rail to leave the church, a woman came behind me and touched my arm. When I turned toward her, I could see her hand open and waiting for help. My spirit was refreshed by a time of prayer, I reached into my pocket and gave her a coin. When the money touched her palm, she opened her mouth. In the dimly lit church, her jaws became like a cavern of anguish that seemed to swallow all remaining daylight. She had no teeth and her waggling tongue vibrated with the sudden energy of a rallying cry. The woman called her friends. I had been singled out as one who would give. Immediately, a throng of beggars pressed against me, all wanting help. I drew back and escaped into the street, hurrying away, sure that I was not meant to provide for all these people.

At times, the expedition itself pressed like a throng of beggars. During the thirty-three-month journey, the question was the same; how much could I give? I had answered that question when we began. I was going to give everything I had. Yet, every moment I was asked for more.

Twenty years after reaching Cape Horn, I was diagnosed with ALL. A bone marrow transplant gave me six years before the treatments I had endured induced MDS. I became transfusion dependent. When MDS morphed into AML, doctors recommended salvage chemotherapy. In 2018, with 40% leukemia blasts in my marrow, I traveled to the University of Washington Hospital for a clinical trial named G-Clam Long Arm, endured a radioactive isotope clinical trial as the first woman in the trial following rats, dogs and three men. Full body radiation was followed by an unrelated donor stem cell transplant.

The journey has not been easy. The beggars I encountered in the church during my paddling journey? I am one of them now. I have eyes of longing. I am on the take with my palm open, hand out, arm raised, and life at stake receiving the sacrifices of bone marrow and stem cell donors. I beg my donor cells to go easy on the attack mode within my system as my graph vs. host disease blooms past acute to severe and chronic. Dr. Sandeep Jain, the ocular GVHD specialist at the University of Illinois, Chicago, evaluated my Ocular Surface Disease Index score at 83.3 with a symptom intensity of 6/10 termed “Distressing/Miserable.” My tear production is zero, injured beyond repair. I invited the Wisconsin Department of Human Services, Office of the Blind and Vision Impaired when I was at the mercy of state services and contributions of adaptive equipment so I could know what time it is. In a world of pain and blur, I learned to close my eyes and listen more intently. Asking my children to read to me. Drive me to an appointment because I am no longer able. Hoping doctors do their homework. Panhandling for persistent, dedicated researchers. Scrounging for clinical trials. Entreating schedulers to find an appointment for me with the next recommended expert. Seeking Angel Flights and the kindness of volunteers, friends, and family to deliver me to medical centers. Becoming a vagrant, waiting for the lab tech to go easy with the stick and promise not to fish with the needle. “Draw blood the first try,” I tell them. “Use heat compress

Valerie checking into University of Washington Hospital for salvage chemotherapy with GClam LongArm clinical trial.
and tourniquet,” I suggest to the phlebotomist since I know my body best. When my port, double lumen Hickman, and PICs are removed, leaving one, reliable soldier vein, I strive to place my arm in the best possible position to help the clinical pierce my skin and draw enough to fill the red, green, purple, gold, and/or blue cap tubes with doctor’s orders. I rattle the cage when a test resultant is not forthcoming. I demand another provider when the lumbar puncture goes bad with my body curved in a fetal position, facing the wall on the procedure table as the first assigned provider pokes multiple stabs without finding the open space between vertebra. I ask the nurse to hold my hand as the doctor begins pressing my pelvis to find where to place the needle for a bone marrow biopsy and aspiration. I beg my health insurance not to run out. When I am in the hospital, I beg to return home. I hope for a twenty-dollar bill to surface in my wallet, or a credit card that has not maxed its limit to meet another co-pay or call a specialty pharmacy to extend credit. I track down social workers for food, gas gift cards, cab vouchers to still the tide of my evaporating finances. I rustle grants, heat credits, food stamps, and loans, tapping the equity of my house and car to pay the bills. I sit across from hospital financial aid officers making applications for reduced or waived payments on my bills. Instead of a princess sticker as reward following procedures, I squirrel away juice, cheese, and snacks to bolster my food security. During infusion procedures, I ask for double the snacks I can eat and stuff my purse for treats to munch on later. I seek bargains on clothes and shoes for me and my children at rummage and garage sales. I bargain with myself to get out of bed, beat the incessant fatigue and flex my steroid melted muscles, stripped bones, frayed joints, and fragile, thin skin compromised by treatment. I beg for my voice and body to be counted rather than submitting as a data point, guinea pig, or lab rat. I beg the pharmacist to tell me the side effects of each new medication even while the doctor orders the drug, upholds protocol, and cautions the downside of not swallowing the elixir. I beg for peace and understanding to accept my new normal even as I recognize the dynamics of apogee – the developmental culmination of the moon orbit in the position farthest from the earth – seeking orientation in my position as cancer patient in territory I had never imagined or asked for while struggling to find baring and purpose for my altered life farthest from where and what I knew myself to be before cancer.

Grace is abundant. Without asking, I am showered with cards, prayers, cancer caps, wig, lap robes, smiles, encouragement, demonstration and the practice of courage in the world of cancer survivors, caregivers, and donors. MDS Foundation, Be the Match Foundation, American Cancer, Blood and Marrow Transplant Info Network, and Leukemia/Lymphoma Societies are sources for newsletters, webinars, conferences, websites stocked with information, free counseling, referrals, grants, and more. Do people bearing gifts, institutional staff and volunteers

AML PATIENT STORIES

Halloween at the hospital. Valerie dressed with Survivor t-shirt, carrying a bag of her empty medicine bottles, using a barf bag to collect candy.

Valerie’s bone marrow biopsy enroute to lab for testing.
realize their work and kindness are critical for so many of us?

People tell me they do not like asking for help, and prefer independence. I remind myself and other advocates of pulling oneself up by bootstraps that we are conceived dependent in our mother’s wombs. We are born dependent. Surviving cancer is a great equalizer, dependent on the kindness of others even when we hide in bed with covers pulled over our heads, exhorting the world to go away, while grappling with the necessity of support teams and wondering who amongst family and friends are willing to come alongside. Sometimes I notice a new best friend in the patient beside me. We are two bald heads speaking cancer language.

I cry out to God for another day of being alive. I beseech thee, O Lord, for mercy. Victim is not the word I use or the place I want to be. In the midst of my circumstance, gratitude is bedrock and overarching privilege on the journey to well-being. I advocate for wholeness and healing. Begging that I can take up my pallet and walk with the army of survivors moving forward into a new day.

Cancer reminds me of my 21,000-mile canoe journey from the Arctic Ocean to Cape Horn. During my decade of cancer and treatments, the question is the same. How much can I give? I am giving everything I have, even as every moment I am asked for more. And, I am receiving more love, learning, and care, while energized with a rallying cry of thanks!

Valerie Fons is a cancer survivor of ALL, MDS, and AML, a bone marrow transplant in 2010, and stem cell transplant in 2018. Diagnosed with MDS in 2016, doctors told Valerie she was dying. In response, she wrote lyrics of affirmation and life set to the melodies of popular show tunes. The American Transplant Games heard Valerie’s songs and accepted her as a participant at the 2020 games in the vocal lyrics category. In July, 2020, she will be singing her good marrow songs in Meadowlands, New Jersey. She lives on Washington Island with six adopted children, her husband Joe, and a dog named HOPE.
Do you...

KNOW AML

ACUTE MYELOID LEUKEMIA

also called AML, is a type of cancer that affects the stem cells in the bone marrow. It is one of the most common types of leukemia in adults, but can develop in children too.

SIGNS & SYMPTOMS

AML develops quickly, which is why it is termed “acute”, and is often diagnosed at an advanced stage. It is important for everyone to fully understand the signs and symptoms to ensure a diagnosis is made as early as possible.

Here are some of the general signs and symptoms of AML to look out for:

- WEIGHT LOSS
- TIREDNESS OR FATIGUE
- FEVER
- LOSS OF APPETITE
- NIGHT SWEATS
- BLEEDING/BRUISING MORE EASILY

KNOW AML

Know AML is the first global AML awareness and education initiative. Our goal is to facilitate and improve AML knowledge worldwide and develop community-based initiatives to overcome current and future challenges.

For more information, visit:

www.know-aml.com
Simply put, my cancer story is about having faith and trusting your instincts. Of course there are many episodes and a wonderful and important supporting cast and crew. I am the star in this story, but I am also the director. My doctor is the director of photography. He has the “vision” of how to orchestrate my treatment plan. But all decisions are ultimately mine. My best advice to you is: Always be the director in your story. In other words, always have an active roll.

My story begins at the end of 2006. I found myself really struggling through the holiday season. I was 38 and finding it really hard to complete holiday tasks, do my usual weekly errands, and work full time as a registered nurse. At first, I told myself, “Well, you are approaching 40. I guess this is to be expected.” But when I still felt really fatigued after the holidays were over and I woke up a few times with sudden but brief chest pain in the middle of the night, I went to my doctor and said, “Something is wrong”. The EKG was normal so my doctor sent off some blood work. The next morning she called to tell me that there must have been some error at the lab because the results were “weird”. She wanted me to come back for a redraw. Two days later she called and said, “Your repeat bloodwork came back even more abnormal. Your CBC is extremely elevated and that means there is a hematological event happening. We need to get you in to see a specialist ASAP”. Her voice faded and everything around me blurred into the background. My Cancer Story had begun.

My official diagnosis came in March 2007 after a slew of tests. I remember the lab tech making slides with my bone marrow and wanting to grab them up and hide them. I knew people were going to look at those slides under a microscope and pick them apart and list all the irregularities and that made me sad. They determined I had Myelofibrosis (MF), the most serious of the Myeloproliferative Neoplasms (MPNs). No definitive cure or real treatment at the time. The good news was that MF is usually very slow progressing. The bad news was that there was nothing they could do about the fatigue. It was now my new normal. My doctor, Dr. C, told me, “Only God knows your expiration date. So go out there and live your life fully!” He told me there was promising new research happening which would hopefully mean treatment options in 5–7 years. And stem cell transplant would be our back-up plan. He thought I could coast for 5–10 years. I decided I would look at my journey with optimism. My parents gave me a T-shirt that said “Attitude is EVERYTHING! Pick a good one!”. Instead of a dramatic single movie story with a sad ending, I was going for a sitcom with many seasons.
In Season 1, I focused on learning new ways to stay as healthy as possible and finding better ways to balance my life. The season included a 2-parter where through a crazy turn of events, I found out Dr. C and I both belonged to the same meditation group. It always warmed my heart on the nights when I looked up from my cushion to find Dr. C on the cushion beside me. It was a hug from God. I felt confident in my team and treatment plan and periodically God sent signs to reassure me. By Season 2, I had lost perspective of how fatigued I actually was. I just went on living a crazy but very happy life.

I made it to Season 6 with very little change in my health. Then my hematocrit became really high and my very thick blood caused me to be very fatigued. I began going once a month to have 500 ml of blood removed. I’d have to receive a fluid bolus to replace the volume or I’d pass out. I continued to feel weak, and the resulting low iron from the frequent phlebotomies caused constant irritable leg syndrome. I never slept well. Life was difficult.

Over time, my symptom load gradually increased and in Fall 2014 it reached a life altering level. Dr. C had retired and in a magical episode in Season 8, God directed me to Dr. S. In 2015, Dr. S started me on the drug Jakafi. It was one of the discoveries resulting from that research Dr. C had told me about in 2007. Season 8 was like a new beginning. Living a low symptom life was AMAZING!! I was able to volunteer as a mission nurse in Honduras again, and run in 5K races. I did more traveling too. The great response to Jakafi lasted through Season 10. And then the symptoms started drifting back and my blood started showing new changes. We were at a crossroads.

Before I can tell you about Season 11, I need to do a little recap. In summer 2016, when I still was in that low symptom phase, I needed to do a little recap. In summer 2016, when I still was in that low symptom phase, I was at work. My coworkers were discussing the upcoming season of college football. John was being boastful about his Louisville Cardinals and Jenn was praising her beloved Clemson Tigers. I never had followed football of any kind, so I was not participating in their conversation. Eventually John insisted I join in and at least pick a side if I didn’t have my own team to support. Simply to antagonize John, I said, “Okay, I choose the Clemson Tigers”. I didn’t even know what part of the country Clemson was in! I did a little research about Clemson, SC, the University, Coach Dabo Swinney and the players. I started getting attached to those Tigers. I also studied the rules of football. My intention was to learn enough so I could adequately razz John. But Clemson was doing well that season and I quickly got drawn in. I told him “We” (Clemson) had “Tiger Power” and we would win the National Championship. The crazy thing is, WE did!! From then on I was hooked. I used the phrase “Tiger Power” to proclaim the reason behind victories for Clemson or myself personally. #TigerPower became part of my identity.

Now back to spring 2017. Things were changing and not in a good way. Dr. S gave me options. My gut said “No” on SCT. He had a brand new clinical trial that he was especially excited about but he was hesitant about enrolling me. The new trial involved paring the Jakafi I had been taking with an investigational drug. These drugs had never been paired before, and Dr. S said there was a risk it could cause harm. A low risk, but still a risk. He did have a patient in the trial that had recently achieved remission, so it was worth at least thinking about. I went home and started

Eventually John insisted I join in and at least pick a side if I didn’t have my own team to support. Simply to antagonize John, I said, “Okay, I choose the Clemson Tigers”. I didn’t even know what part of the country Clemson was in! I did a little research about Clemson, SC, the University, Coach Dabo Swinney and the players. I started getting attached to those Tigers. I also studied the rules of football. My intention was to learn enough so I could adequately razz John. But Clemson was doing well that season and I quickly got drawn in. I told him “We” (Clemson) had “Tiger Power” and we would win the National Championship. The crazy thing is, WE did!! From then on I was hooked. I used the phrase “Tiger Power” to proclaim the reason behind victories for Clemson or myself personally. #TigerPower became part of my identity.

Now back to spring 2017. Things were changing and not in a good way. Dr. S gave me options. My gut said “No” on SCT. He had a brand new clinical trial that he was especially excited about but he was hesitant about enrolling me. The new trial involved paring the Jakafi I had been taking with an investigational drug. These drugs had never been paired before, and Dr. S said there was a risk it could cause harm. A low risk, but still a risk. He did have a patient in the trial that had recently achieved remission, so it was worth at least thinking about. I went home and started
researching the investigational drug. It was not yet named so it was known by the alphanumeric the FDA had assigned to it. I didn’t notice it right away, but in the name was a sign. When I saw it, I knew instantly that I had to enter that trial. The investigational drug was TGR-1202. TGR as in Tiger! It had Tiger Power!! God had set in place the series of events that led to my becoming a Clemson Tiger fan so I’d see the “Tiger Power” sign and not be afraid of the clinical trial. It all made sense that I had suddenly become a college football fan at the age of 47! I told Dr. S my Tiger Story and that 2 was my favorite number. “I will be Patient #2 in remission! “You just watch”, I told him. He chuckled and said, “Okay, let’s go for it!” I started the clinical trial in July 2017 and wore my Clemson Tigers T-shirts and sometimes tiger ears to my weekly clinic appointments. Dr. S calls me Smiley Riley, and soon the staff all knew about Smiley Riley in the tiger ears who insisted she would achieve remission. Everyone was so supportive! I have photos of some of them in Tigers ears too! By November, to everyone’s delight, I had, in fact, reached complete remission!! I’ve enjoyed telling my Tiger Story over the years. If you keep an open mind, I believe there are messages for all of us to help guide us on our paths.

Complete remission means complete cessation of symptoms. My CBC is now normal and my precious bone marrow has no irregularities for someone to list. I feel better today than I did in my thirties. I remain in the clinical trial for now and recently passed the remission 2 year mark. We are not sure what the future holds. We will keep riding this wave for now. Season 12, 13 and now 14 is all about living a full life without limits. I joined Iron Tribe Fitness and do High Intensity Interval Training (HIIT) under the careful watch of my coaches. I run, jump up on boxes, lift weights and do real pushups! I also trained for and ran a half marathon. I celebrated my 50th Birthday in Ireland with friends. An important Bucket List achievement. I became a Clemson donor in 2018. College Football is now one of my passions. Me, Jenn and John have started the tradition of going to the Clemson vs. Louisville game together with our families each season. Life is good and full of new opportunities!

My doctor and I decided that we needed a patient support group in our part of the country. He wanted me to include MDS along with MPNs because they have recently discovered that these diseases overlap. They are like cousin diseases. So I started a private Facebook page called Nashville MPN/MDS Support Group for patients in Tennessee, Southern Kentucky, Northern Mississippi, Northern Alabama and Northern Georgia. Right now we offer support via the group page only but we hope to hold meetings several times a year once we have enough interest in formal meetings. I also plan to try Facebook live sessions in 2020 as an additional way to connect patients. I sit on the MPN Research Foundation Impact Council to help the MPNRF identify patient needs and provide feedback regarding projects and outreach activities. I recently attended an MDS Foundation Patient and Family Forum in Nashville to educate myself about MDS. I am hoping to find a few MDS patients in my area to help me with the group and to be administrators on the Facebook page. I have received so much support from so many wonderful people over the years. I would like to pay it forward and help as many patients as I can.

One of the mottos at Iron Tribe Fitness is “Stronger Together”. I think that applies for Cancer patients too.
While I’ve been generally healthy for most of my life, I’ve had several instances of elective or emergency hospitalizations. The first of these involved a bleeding ulcer in which my hemoglobin dropped to around 6-7 g/dl. I was treated in a hospital in California, at the very beginning of the AID’s crisis. Although there were no tests for AIDs, I was going into shock and received my first transfusion.

Several years later, I had another ulcer, and received my second transfusion. After this I began being much more conscientious about routine physicals, and became a 4 gallon Red Cross blood and platelet donor. I was also continuing to battle lifelong weight, cholesterol and high blood pressure issues.

In January of 2014, I discovered that I had atrial fibrillation. After running many tests, my cardiologist performed a cardioversion to correct the issue. While this seemed to be successful, a few weeks later I began experiencing some angina like symptoms. After performing an angiogram, we realized that I needed a quintuple coronary bypass.

A few months after surgery, my cardiologist told my primary care doctor, that I had macrocytic anemia. My primary care doctor realized that I needed to see a hematologist.

Dr. Abby Bova had already taken care of my wife’s breast cancer, and we knew that she we was the perfect fit for us. She quickly ordered every conceivable test for me, including a bone marrow biopsy. This time the results showed that I had 4 mutations, as well as altered chromosomal results. My LDH levels were substantially elevated, my neutrophil count continued to rise, and we were now detecting blasts in my peripheral blood.

Dr. Bova wanted to prescribe “Jakafi” (Ruxolitinib), as well as “Vidaza” (Azacitidine). She found that there was with the anemia, seemed to be consistently in the “Normal-Low Normal” range.

When we returned to Oklahoma City, Dr. Bova repeated all of her earlier lab tests, including a new bone marrow biopsy. This time the results showed that I had 4 mutations, as well as altered chromosomal results. My LDH levels were substantially elevated, my neutrophil count continued to rise, and we were now detecting blasts in my peripheral blood.

Dr. Bova wanted to prescribe “Jakafi” (Ruxolitinib), as well as “Vidaza” (Azacitidine). She found that there was only one Phase 1 trial in the country using them. The trial was at MD Anderson in Houston. She contacted Dr. Naval Daver, lead investigator in the trial, and submitted all of the data she had on my case.

MD Anderson contacted me in just a couple of days. We drove to Houston, repeated all of my original testing and confirmed all original tests. I returned to Houston in two weeks and was now officially admitted to the study. I had an official diagnosis of MDS/MPN-unclassified.

I have now had three months of Jakafi alone, followed by another bone marrow biopsy. After completing that regimen I had three months of combined Jakafi/Vidaza therapy, followed by another bone marrow biopsy. That biopsy showed no increase in blasts, and no evidence of a clonal neoplasm. In another month I will have a third “staging bone marrow biopsy”.

While my white counts are behaving nicely, I am becoming transfusion dependent. We have mutually agreed that a hemoglobin level of less than 8.0 mg/dL warrants a transfusion. I have had about 8–10 transfusions at this time. My ferritin concentration is approximately 1,500 ng/mL. We are aware that Vidaza is causing myelosuppression at this time, but we are also confident that it will eventually allow my hemoglobin levels to rise.

During my last visit with Dr. Daver, I was asking him a question about some of my genetic results. He simply said, “You’re a scientist, you’re aware of the statistical variability in any laboratory measurements.” It is very important to me that both of my Doctors value my input, and that I am involved in making decisions that all of us are comfortable with.

I’ve had the opportunity to be actively involved with research at places like Johns Hopkins, Mt. Sinai, University of Arkansas for Medical Sciences, and the University of Maryland. I can’t conceive of a better team, or overall medical care that I am now getting.
Let me share some final quick comments with you.

(1). As I stated earlier, there are some particular things that I intend to do. I have a very complicated initial diagnosis. As far as Dr. Bova is aware, I am the only person in the entire 4 state Mercy medical system to be receiving both Vidaza and Jakafi. I’m also the only crossover patient (MDS/MPN) to be getting these medications. My clinical trial lasts for five years, and hopefully I may produce some interesting results by then.

(2) There are also things that each of you can do. First and foremost, your “primary caregiver”, wife, husband, other family members, etc. are among your most important assets. Always try to give them as much consideration as they give you. Aggressively maintain the other valuable contacts that each of you already have. I’m convinced that the level of achievement that I was able to access in my early career came from the fact that I’ve been able to maintain those contacts for many years.

In many of your comments, and in questions we’re asked during our treatments, we’re reminded that spiritual support is vital to our well-being. Most of the places where I’ve worked, or been a patient, offer not only superior medical care, but have direct Christian or Jewish institutional support. My very close friend, and Laboratory Manager, Dr. Phil Kemp, leads a Bible Study at the Federal Aviation Administration. This is one of the most incredible groups that I’ve ever been involved with. The Naval Academy Chapel was also a strong reminder of the importance of a “Spiritual Anchor” to our lives.

Every day that I was a Hopkins fellow I would pass through the old main lobby, and see a 9-foot statue of “Christ the Healer”. While Hopkins represents excellence in medicine, this was a constant reminder that there is a power beyond even what the world’s best physicians can do.

(3) Another very important support that you have comes from your fellow patients. My original “MDS buddy” (the same one my father treated many years before), told me when we first met “I have this tattooed on my forehead, the drugs work until they don’t”.

Several weeks ago, two of us were getting Vidaza treatments. I asked the fellow next to me if he had MDS. He didn’t know what that was. I asked him why he was receiving injections, and he told me that he had AML. When I asked him how long he had been treated, he told me that he’d been receiving treatments for five years. I was really stunned to find that there was a fellow right next to me that had the very condition that I had thought was supposed to be “the end of the road” for MDS patients. He seemed to be doing very well to me!

CLOSING THOUGHTS

When I think of the comments of my “MDS buddies” I realize that none of us know how our medical conditions may progress, but we can choose to not let that fact control our lives.

For my part, I am preparing to retire, and try to carry out some of the things above that I’ve already said that I can do. Frankly, the single most important thing that each of us can do now is rejoice in each new day that we’re given and “Make Memories”.

Thanks for reading “my story”; I hope you enjoyed reading it as much as I’ve enjoyed writing it!
CONTRIBUTIONS TO THE MDS FOUNDATION

THANK YOU

Roger and Diana Abbott
Barbara Ackley
John Adams
Amelia Adams
John Adams
Joni Adams
Marcelle M. Adams
Mark and Deb Adkins
Rich Ahearn
Phyllis Allen
Edward J. Allgeier
Rob Allred
Brian Scott Anderson
Judith Anderson
Barbara and Charlie Anderson
Rodney Anderson
Doug and Carolyn Andrews
Angel’s Security Corporation
Jennifer Angove
Glen D. Aspinall
Merry Atwood
Kenneth N. Baker
Grace Baker
Stacey Baker, PhD
Charlie Baltstad
Anthony W. Barker
Claude and Maryann Barone
Dino and Gloria Barone
Barbara Bartlett
Lawrence Bechler
Jack Becker
George Beeman
Tony Bell
Marie Belpusi
Raymond Michael Bennert
Dr. John M. Bennett
P. Bruce Benzler
Stephen John Berger, Sr.
Marvin Berlin
Robert Bernhard
Joan Bersofsky
Beth Birnbaum
Naomi Bisk
Diana Blair
Bernard Blessinger
Katherine Bliss
David Blivaiss
Duane Bogenschneider
Marian Bond
Don Borth
Diane Boyer
Zay and Cinnamon Bradley
Demos Brands
David Bremm
Elizabeth Brennan
Mary Bressette
Diane Brizer
Logan Brown
Sally Brown
Nancy Bruch
Dennis and Barbara Bruns
Ian Buchanan
Janice Buckner
Theodore and Linda Bucon
Charles Buess
Lori Bungarz
Donna, Dave and Davy Bunton
Melanie Burch
Ruth Burgess
Richard and Ann Burgy
Carol Burns
Michael Busalaki
Robert and Ellen Busch
Jennifer Buxtin
Doris Faye Byer
Michael Byers
Kasha Cacy
Amanda Cadle
Gioavanna, Brendan & Bruno Caffrey
Anne Cahn
Louis Camhi
Patrick Cammarano
Maria Campano
Vicki Capp
Justine and Joe Cardone
Dorothy Carlisle
John and Alice Carlstrom
Rosalie M. Carothers
Allison M. Carroll
John M. Castner
Tony Cervone
Belinda Chadwell
Daniel Chambers
Jennifer Chambers
Kevin Chambers
Meghan Chambers
Victor Chang
Antonia Charles
Mary & Leo Chimienti
Randolph & Elizabeth Chinyee
Mary Choplosky
Rebecca Christianson
Michael and Joann Cinque
Sarah Cissna
Citizens Deposit Bank
Curtis Clark
Virginia Clark
Victoria Clifton
Thomas Coccagna
Alexis Cocco
Lowell Cohen
Amy Cole
Cheryl Coleman
Robert H. Collins, Jr.
Conklin
Seraphin Joseph Conley
Connie Connelly
Kathleen Connoy
Adam Considine
Rose and Ron Conti
Doyle C. Cook
Marilyn Copeland
Norma L. Corbin
Marissa Cortese
Joseph and Marion Cotton
Ashley Coulter
Ann Brody Cove
Jeff and Cheryl Cowan
Marianne Cowing
Fred and Carol Coyne
Mike and Pat Crilly
Matthew Cristadaro
Jeffery Kahn & Genie Croft
Ed and Pat Crowe
Maureen Crowley
Neil and Ruth Cuadra
Sylvia Curtis
David Cushman
Mark Cushman
Rita & Bruno Dacanay
Raymond P. Daniels
Mariana Daniels
Peter Danielsen
Douglas & Kristen Davenport
Jennifer Davidson
Vickie Davidson
Peggy D. Davies
John Davis
Trevor Davis
William Bell Davis
Vernicia Dawson
Linda Day
Andrew Dayney
Kevin De Sa
Deborah Dean
Sandra, James and Sara DeCarle
Ella Mobley Deese
Mary Deming
Lauren Dennis
Kyle and Kristin Denton
David and Mary Deucher
Sheila and Marci Deyo
Melanie Diamond
James & Josephine Diedrich
Dennis D. Dillon
James and Ann DiMattia
James and Meg DiMattia
Joan Dion And Family
Sheereen Docktor
Jennifer Doggett
Mark Doherty

The MDS Foundation relies on gifts to further its work. We would like to acknowledge the generosity of the following individuals and organizations that have recently provided gifts to the Foundation:
CONTRIBUTIONS TO THE MDS FOUNDATION

Nancy and Larry Dolph
Gayle Donaldson
Paul Donovan
Ted Dorf
Stan and Suzanne Dorf
Advised Fund of the Jewish Community Foundation
Elizabeth Doriot
Lea Dottke
Kristin Dowling
Nancy Downes
Melissa Drahlzal
William C. Drotleff
Karen Dumas
Sheryl Dunsmore
Theresa Duran
Regina LaRosa Durante
David Dyson
Victoria Connor Eagen
Barbara Earl
Henry Earl
Douglas Edmunds
Meriam Eklund
John Elley
Jean Ellis
Nancy Ellis
Doris Emmons
Richard Epler
Mary Epstein
Ernsteen Family Foundation
Randi Falow
Susan Fast
Ellen Faulds
Mike and Louise Fedora
Janice R. Feely
Jane Felder
Laurel Feldman
Mike and Susan Feldstein
David and Shirley Fenner
Carmen Fernández
Robert Ferone
Fertig Freedom Foundation
Andrew G. Feuerstein
Susan Feulner
Alicia Finnegan
Dave Fisher
Linda Fisher
Philip and Myra Fishman
Kathy Flaherty
Nancy Fleming
Dorothy J. Flett
Emil Fleshman
Lewis Flock
Ekaterini Fokas
Bob and Gerry Forster
Fort Sanders Regional Medical Center Case Management Dept.
Nicolas Fosdick
Thomas Frank
Patricia Freudenburg
Elizabeth Frey
John and Beth Frey
Robert and Sara Frey
Melinda Friedenberg
Susan and Allen Frisch
Joseph and Patricia Fritz
Anita Froistad
Nancy Gabriel
Nancy Gallba
David Galli
William and Norma Gangloff
Michael Ganley
Jerrie Gann
Bonny Gantz
Kathleen Gauthier
Margaret Gavin
Joan R. Callaway and Julie C. Geddis
John Bovair and Dave Gentry
Tammy Gerber
Ulrich Germing
Peter Gettner
Steven and Beth Gilford
Gary Gillen
Ron and MaryBeth Gilligan
Richard Ginsburg
Thana Giridhar
Paul Glickman
Jeffrey Glover
James and Judith Gmiter
Catherine Goff
Dr. Stuart L. Goldberg
David Goldberg
Lewis and Sylvia Gollub
Hayden Gomes
Marsha Gonda
Matthew Gonzales
Goodman Real Estate Services Group
Judy Goodyear
Rick and Sue Gordon
Susan Gorenflo
Ilga Gottlieb
Laura Lee Gramstad
Granby Memorial High School Field Hockey Program
Stancye Granger
Jerry and Renee Green
Dr. Peter L. Greenberg
Tina Greene
Eugene Gregory
Teresa Gregory
Patricia and Brenda Grell
Elizabeth Gretton
Dwight Griesman
Victor Groner
Teresa Gross
Vesna Grujic
Amy Gustafson
Robert Hackworth
William Haeger
Stacy Hagemann
Louise Hahn
Larry E. Haigh
Robert Halleck
Heather Hargrave
Harleysville YMCA
Early Childhood Center
Judy Harrelson
Paul Gish Harvey
Mitra Hashtroodi
Jonathan and Mandy Hasty
Theron and Brooke Hatch
Sue Hauck
Robert and Judith Haynes
Jim Heiland
Paul and Julie Hellenbrand
Freyja Helmer-Sindemark
Heidi Helmich
Raymond M. Hencken
Christine Miller Hendrix
Arnold J. Henig
John Hennessy
David Hensel
Kay Herrmann
John Heveran
John Hindes
Diane Hinojosa
Brent Hladky
Katherine Hobbs
Fae L. Hoffman
Stacy Hoge
Thomas and Betty Holder
Michael Hollander
Carol Holman
Sara Holmes
Anna Holness
Adrienne and Ira Holtzman
Ellen Hooley
Bill Hopkins
Melinda Hopper
Cora Horton
William and Barbara Howard
Robert and Kathleen Howell
Antoinette Huber
Cecelia Hudzik
Paula Hultman
Karen Hunt
Richard and Sally Hyatt
Sandra Hynes
William R. Iber
Sharon Ingraham
Chris Ivanonko
Keith Jackson
Barry Jacobs
Claudette Jacobs
Lauren Jacobs
Herb and Beverly Jacobson
Judith Jager
Rachna Jain
CONTRIBUTIONS TO THE MDS FOUNDATION

Keith and Joan Jansen
Jay Jeffcoat
Thomas and Patsy Jenkins
Tony Jensen
Louis and Kathy Jerge
Jewish Community Foundation of the Milwaukee Jewish Federation, Inc.
Leonard A. Jewler
Pam Johnson
Rita Perisin Johnston
Cecile Jolin
Gregg Joly
Diana Pappas Jordan
Diana Jose
Charlotte Joynt
Wade Judge
Linda Kaase
Amy Kahn
Jeffrey Kaminski
Victor and Barbara Kaminski
Jeffrey Kane
Phyllis Kaplan
Diane Kaufman
Sharon Kaye
Michael Keefer
Attila and Jana Kekesi
Vasken Kelerchian
Elizabeth Kennedy
John J. Kennedy
John Arthur Keough
Robert and Andrea Kerlan
Phyllis Kerr
John and Mary Khym
Sally Killick
Phil Kimball
Alexis Kimber
Steve Kincaid
Kimberlin Kincaid
Steve Kincaid
Michelle King
Walt Kirchner
Ronni Kirsch
Janet Klagholz
Adrienne Klein
Meryl and Mark Klein
Richard Klein
Bob and Laura Koestner
Adam Kohnman
Mary Pat Kollitz
Marjorie Kosic
Karen Kramp
Sandra K. Kratz
Donna Krauss
Ramesh Kumar
Michael Kurman
Rick and Lori Kuroskaka
Robert Laccone
Lake James Breakfast Group
Leonard and Dolores Landi
David Landis
Judith Lane
Joanne Lasley
George Latsko
Susan Laufer
Joyce Law
Kevin Lawlor
Thomas Leclerc
Connie Lee
Ji Young (Claire) Lee
Nina Lee
Patricia LeHoullier
Leon Lejda
Marjorie Lejda
Lisa A. Lenhart
Frederic and Kathleen Leverenz
Resa Levy
James Lewin
Robert Lewis
Suzanne Lewis
Joey Lindstrom
Andrew Lindvall
Irwin List
Mark R. Litzow
Rebecca Long
Salli and Al Long
John Loper
Rocco LoPiccolo
David Lorah
Michelle Lord
James Lovell
Trisha Ludlum
Cheri Lundblad
Bill and Kathy Lyons
Dorothy MacCormack
Janet Magnemi
Louis Mahaffey
Cathryn Majchrzak
Edward and Carol Major
Giuseppe Mallimo
Allan Malvicino
Julie Manas
David Mandell
Phyllis Mandell
Ambuja Manoharan
Mary Jane Marculaitis
Marlene Marcus
David & Mitchell Friendburg, and Alan & Alissa Margulies
Linda Marie
Peter Mariniello
Richard Marks
Jerry and Anne Marquardt
Susan Marr
Sheila L. Martin
Susan Martin
Pat Marzetta
Deanna Masgay
Harriet Mass
Thomas Matkins
Paul Maynard
Anthony & Brenda Mazzocchi
Jane McAuliffe
Larry McBride
Bob McCabe
Ann McCarthy
James R. McCleod
Daniel McCormick
Debra McDermid
Mary L. McGrath
Julia McGuire
Jennifer McNichol
Marie McJilton
Nina McSherry
Roger Meessen
Patricia Meling
Danise Mena
Raul R. Mena
Ana Merchant
Wayne Metsch
Gerry Meyer
James Meyers
Russell Miah
Beth Micenko
John Michalec
Marcelle Michalski
Charlotte Milan
Helena Miley
Tessa Millard
Bruce Miller
John Miller
Lois Miller
Lynn and Steve Miller
Malcolm and Marilyn Miller
Milt Miller
Ned Miller
Betty Jane Mincemoyer
Lynn Minnis
Scott Mitek
Mary Miyawaki
yasushi Miyazaki
Kenneth Mock
Jo Linda Moore
Kevin Moore
Susan Morales
Jim Morelock
Beverly Morhange
Deborah Moroney
Timothy P. Morris
Judy Morvay
Edith Ann Mrazik
Pamela Morczkowski
Matthew Mucci
Harriet Muit
Jane A. Mullen
Bonnie Murphy
Joan Murray
Joseph B. Murray
Bobby Myers
Susan Natali
CONTRIBUTIONS TO THE MDS FOUNDATION

Dennis S. Neier
Marisha Krupkin & Dennis Neier
Curt Nelson
Dr. Stephen D. Nimer
Suzanne Nixon
Edmund Oasa
Scott and Annemarie Oats
Carolyn O’Brien
Mary O’Connell
Susan O’Connell
James J. O’Donnell, III
Office of Animal Welfare
James O’Gorman
Jesse E. Oldham, Sr.
Eleanor O’Leary
Bernard Olsen
Ken and Sherry Olson
Amy Oseland
George Ossman
Ernest and Dolores Ott
Mark Owen
Shelly Purcell-Owens
Marilyn Painter
Frank and Eileen Palmieri
Steven and Vickie Paluska
Paoli Hematology Oncology Associates, PC
Elizabeth Papetti
Jill Parker
James Patrick
Elizabeth Patterson
Marija Pauly
Brian Pearce
Steve and Rosemary Pearson
Richard Pegg
Deborah J. Peirce
Barbara Peixoto
Lorenzo and Joan Sharon Pelosi
James and Susan Peluso
Dolores McDonald Pendell
Russell Pennelly
Pennsylvania State Police
Nick Perisin, II
Brett Peroni
William Pesek
Peter Kim – Eastern Corporation
Bart and Laura Peterson
Edward and Angela Petrantos
Lauren Peyton
Murray Peyton
Robert and Sally Peyton
Jennifer Phillips
Merle Phillips
Debbie Pianin
Karen Pierson
Gina Marie Pitti
Michael and Donna Pizzulli
Mary E. Plante
Julie Platanihas
Jane E. Pope
Brian Potter
Marcia Powell
Eddie Preijers
Hendrik and Diane Preijers
Thomas J. Preston
Mike Price
Judith M. Price
Joyce Printz
Geoffrey Propheter
Jeff Quaintance
John Kaase Racing
Alaric Radosh
Katherine Radosh
Kathleen Ramassini
Kim Ramer
Clement and Joan Rancourt
Teri Rankin
Marlene Hoffman and Brett & Jayme Rapp
David Rascher
Maureen Ratliff
Jeanne C. Rechenmacher
Rick and Sandra Reed
Loretta A. Reiner
Louis Resnik
Sandra Rexroat
Mary J. Rhode
Thomas Richardson
Bob and Marcia Rider
Erin Riggle
David & Mary Ann Roberge
Esther Rogak
Teresa and Scouty Rogers
David Romano
Joan Romano
Mary Romano and Family
Soo Romanoff
Sara Ronten
Janine Rooney
Harvey Root
Barbara Roper
Charles Rosen
Harold M. Rosenthal, MD
Marian Rosinsky
Mark and Sheila Rosler
Debra Ross
Milton Ross
Pj Ross
Ginger Y. Rosser
Charles Roussel
Kim, Todd, Alexis & Tyler Rudolph
Frank and Mary Ann Rusignuolo
Patti Ruth
Toni Ruth
Lauren Rutigliano
Sean Ryan
Michael Sabloff
Connie and Roger Sakash
Dan and Risa Saltznan
Janet Sammarco
Jim and Judith Sandler
Isaac Contreras Sandoval
Michele Sangatado
Srinivasa Reddy Sanikommu
Monique Della Santina
Darlene Sarne
Marlene Sauer
Abigail Savage
Dr. Michael R. Savona
Charles Scalf
Ron Schachtel
Jesse and Elaine Scharf
J. Thomas Williams, Jr.
and Nancy R. Schauer
Maria Schawiak
Loriann Schenking
Mary Schmidt
Helen Schoen
Joan Schoolcraft
Julia Schuette
Peter Schulkin
Mike and Toni Schwab
George and JoAnn Scimanico
John Scola
Kevin and Jean Scroggin
Alan Seaman
Lynn Seidler
Craig Seifert
Terry and Carole Seiter
Ruth Sencio
Heidi Senick
Senn 61 Reunion Committee
Suzanne Sepety
Elaine Serina
Eugene Serina
Mike Seyler
Patricia Seyller
Stephanie Shaffer
Kathy Share
Ann Sharon
John Shea
James and Barbara Sheehan
Ron Sheets
Karin Sheridan
Jack and Grace Sherman
Jane Sherman
Julie Shervey
Stacey Shoaf
Lori Sholota
Karen Shover
Tim and Lynne Shuey
Jean Shumard
Terry Siegfried
Steve Siehr
Morgan Simon
Suzana Simonishvili
Earl Simons
Kevin Sindelar
CONTRIBUTIONS TO THE MDS FOUNDATION

Barry S. Skikne
Ed and Bette Skok
Claire-Elizabeth Sloan
Kim Slota
Billy Smith
Fred and Rosalee Smith
Linda Smith
Lois Smith
Renate Smith
Diane Sobel
Brian Sode
Theresa Soderberg
Cynda Solberg
Ronald Solberg
Ronda Solberg
Suzanne Soltysiak
Maxine Soriano
Pam Sparkman
Louise Spedaliere
Don and Janet Speer
Frank Spink
James and Jane Springer
Mary Spruil
Eleanor Spuhler
William Stanbach
Stanrose Foundation
Lawrence Staudt
Carla Steger
Kathy Stegh
Constance Stephens
Joan Stimmell
Elizabeth Stohner
Mary Stolfa
Nancy Storck
Nancy Stryker
Pat Stuart
Therese McNeely Stickmann
Ronald J. Stupak
Ruth N. Sturkey
Zita Sulzberger
Nancy Sundstrom
Larry and Rita Susnow
Maxym Sutton
William and Norma Lynn Suvak
Suzanne and Stan Dorf Donor
Advised Fund of the Jewish Community Foundation
George and Rosemary Swantek
Aggie Sweeney
Kimberly Sweeney
Nichol Swenson
Kim Tardy
Ann C. Taylor
Deborah Taylor
Richard P. Taylor
Gods & Heros Tenace
Mike Tersolo
Jerry and Judy Tetley
Heidi Thacker
The Garden Club of Mansfield
The Henry and Marilyn Taub Foundation
The Lester and Grace Maslow Foundation
The Philip and Myn Rootberg Foundation
The Tom and Nancy Bruch Fund of InFaith Community Foundation
The Walterstorff Family
Kathleen Thesing
Carol and John Thiel
Jerry Thompson
Barry and Mary Thompson
Pat Thompson
Dale and Judith Thorne
Angeline K. Thorner
Kristen Thornton
Christopher Thurin
Carol Sue Tittelman
Toiyabe Men’s Golf Club
Mitchell Tolep
Judy Traister
Colleen Trujillo
David Turner
Urban
David Usher
Keke Uzokwe
Rosaria Valenzano
Sandi Price & Leslie Van Derhoef
Roni VanderBroek
Helen Vanskiver
Nicholas Vassiliou
James and Evelyn
Marcie Vinson
John F. Voit
Muriel Vosko
Donlon Wade
William and Alice Walfoort
Jake Walters
Fay Wanetick
Suzanne Ware
Elizabeth A. Wargel
Peter Warner
Carolyn J. Warren
Matthew and Sherry Warshauer
Wanhogs Motorcycle Club
Mt. Clemens Chapter
Virginia Watson
Karen Webber
Stephen Francis
Jim and Patti Wegge
Diane Weidenbaum
Debra Weiner
Claire Weiss
Leon Weiss
Joan and Gene Welch
Doris Welsh
Stacy and Pamela Wenzel
JoEllen White
Veramae Whitlow
Pam Whitmore
Martina Wiedmayer
Jack and Kimberly Wildes
Carol Wiley
Helen Willenbacher
Beverly Williams
Bradley Williams
David and Beverly Williams
Michael and Jean Williams
Robert Williams
Tiffany Williamson
Ralph Wills
Boyd Winck
Page L. Wingfield
Kenneth & Patricia Winkelvoss
Edward Winn
Maureen Wirth
William Wisneski
Hubert and Sophia Wisniewski
Mary and Mike Wolf
Bob and Barbara Wolfe
Charitable Fund of the Princeton Area Community Foundation
Women of the Moose
South Greenville Chapter 1552
Randall Wong
Mary Linda Wood
Catherine Woods
Eileen A. Woods
Susan Woodward
Joan Woolson
Marie C. Wright
Marek Wuw
Ross Wyman
Qing Xu
Kiku Yamada
Lisa and Bob Yanke
Leonard Yool
Garr Youngren
Robin Zegas
Alfred Zelinka
Tony Zertuche
Deborah Zodkowic

ROBERT JAY WEINBERG MEMORIAL

DONATIONS HAVE BEEN MADE BY:
Rochelle Ostroff-Weinberg
Wynnewood, PA
MEMORIAL FUNDS

THE MDS FOUNDATION’S WORK HELPS KEEP MEMORIES ALIVE

MEMORIAL DONATIONS HAVE BEEN RECEIVED IN THE NAME OF:

- Bill Adams
- Angel Andreev
- Jean Avola
- Charles “Ron” Avret
- Vern Lee Baker
- Charles Balstad, Sr.
- James Raymond Barber
- James Barker
- Lois Barnett
- Zdenek “Sid” Bartos
- Ann S. Benedek
- Eric Charles Bergman
- Ronnie Bernhard
- Mia Blumenstock
- Frieda Kupferman Brill
- Sol Brizer
- Eva Brown
- Michael Brown
- Thomas “Tom” Bruch
- Gloria Jean Fournier Bucklin
- Daniel J. Burke
- David Hammond Burke
- Alene Jean Burt
- David Thomas Burtc
- Jewell Calhoun
- Alvaro Cámara
- Leonard Camhi
- John P. Carroll
- Nancy Caruso
- Patricia “Patty” Hurley Cherico
- Byers Clayton Clark
- James Leslie Combs
- Edward J. Connolly
- Patricia Angela Chicone Connor
- Jeannette Cook
- Grady Earl Courtney
- Jerry Cowan
- Stephen L. Crippen
- Thomas E. Criscitelli
- Richard L. Cristadoro
- Clyde Weber Crooks, Jr.
- Barbara Jean Curran
- Donald E. Curtin
- Sally Anne Cushman
- Arthur Cutter
- Joseph Davis
- Walter Lee Davis, Jr.
- Marla DeBonis
- Barbara L. Demers
- Marion Dotson
- Patricia H. Drolette
- Donald A. Dwenger
- Joyce Collier Earl
- Brenda Effron
- Harley T. Emmons, Jr.
- Arthur H. “Bushy” Epstein
- Joseph E. Ernesteen
- Douglas H. Fahreny
- William Felder
- Roger Joseph Feulner
- Bill Fisher
- Suzanne Fleischman
- Paul Arthur Fleming
- Gerald “Jerry” L. Flick
- Andreas Fokas
- Nancy C. Fox
- Ronald J. Foxx
- Susan Mary Frank
- Herbert G. Frey
- Lynn Fristad
- Herbert S. Gann
- Gerald “Jerry” Francis Genaw
- Giri Giridhar
- Andrew Paul Glasgow
- Tereze Gluck
- Robert Goldber
- Kenneth Edward Graham
- Laurie Greenbaum
- Marc Gross
- Vernon Gross
- Thelma L. Hale
- Lester Handler
- Richard Hanson
- Harry John Hauck, Jr.
- Juliane Heggoy
- Martin B. Heiland, Jr.
- Martin Heiss
- James P. Hellenbrand
- Andrew E. Helmich, Sr.
- George Michael Herrmann
- Brad Hoffman
- Kenneth E. Hoffman
- Mary Alice Hudzik
- Kenneth Edward Hunt
- Clifford Ingraham
- Patricia Jackson
- Karen Jacobs
- Robert W. Jarrett, Sr.
- Patrick D. Jeffries
- Esther Jewler
- Mary Catherine Johnson
- Gail E. Jolin
- Don Kane
- Marsha Keefee
- Joseph Keough
- Christopher Masaaki Kimber
- Joe Kirsch
- Cindy Klein
- Roy T. Kobashigawa
- Linda J. Kocherav
- Joseph Kotelnicki, Sr.
- Robert A. Kramp
- Anthony “Tony” Eugene Krauss
- Kenneth J. Kunz
- Claudette Marie Latsko
- Jerry Laufer
- Lucille E. Lenzo
- Ellis Levy
- Joel Levy
- Jacqueline List
- Thomas Eugene Lovell
- John Edwin “Ted” MacNinch
- Sharon D. Mahaffey
- Bessie Mamolou
- Gerald Mandell
- Viviano “Larry” Martinez
- Kate Maure
- Michael J. McCormick
- Leah McDermid
- Linda L. McGuire
- David L. McManis
- Marian Grady McNeely
- Susan E. Mealy
- Wayne R. Meling
- Martin S. Meyerson
- Michael Micenko
- Robert “Bob” Michalec
- Louis “Mickey” John Michalski Jr.
- Andy Michniwicz
- Lee Miller
- Michael Mitek
- Clifford Ken Miura
- R. Howard Moble, Sr.
- Kay L. Moore
- Lillian Morris
- David H. Morton
- David Mucci
- Andrew Joseph Mullen
- Judith “Judy” Klein Murray
- Rosina A. Navag
- Donna Ness
- Patricia Mary Davies Newcombe
- Isabel O’Connell
- Gary O’Connor
- Arlene O’Donnell
- William Francis O’Donnell, III
- Robert Wayne Ogleby
- Daniel C. Olmizzi
- Judith Olsen
- Gloria Ostrowski
- John F. Papetti, Sr.
- George Joseph Paterni
- Susan M. Patrick
- Franklin Herbert Pennell, Jr.
- Paul E. Pennie
- Nick J. Perisim
- Joseph A. Perkins, Jr.
- Tony Perla, Jr.
- Charles I. Peterson
- Dorothea Phillips
- Ralph Phillips
- Kieran Pillon
- Livio Pizzinat
- Christien Freijers
- Armando Pulvera
- George Wayne Renniger
- Phillip L. Renzetti
- Marcia E. Resnik
- Steven K. Rhoads
- Ajel Ritchy
- Thomas W. Robertson
- Abraham (Abe) Rosenthal
- Maureen Anne Rouleau
- James Michael Ryan
- Peter R. Sammarco
- Arthur Howard Sattin
- Allida Emma Sauer
- Cathy Schmidt
- Stanley Scholosohn
- Walter H. Schoolcraft
- Mildred Marie Schuette
- Brian Schwartz
- Merle Schwartz
- Stephen Scholinsky
- William John Seelie
- Irving Seidman
- Kathleen Seiffert
- Sol Iris Sepulveda
- Dr. Eliseo B. Serina
- Donald M. Shachat
- Marlene Shervey
- William Shuey
- Thomas H. Shumard
- Joyce Simeon
- Ruthanne Simons
- Donald R. Smith
- Jean Marie Sode
- Ronald Solberg
- Leon A. Soltyssiak, Jr.
- Michael Sortino
- Jerry E. Spann
- Eddie Neil Speer
- Raymond P. Stohner
- Patricia Davey Stuck
- David Sundstrom
- Lillian “Lilly” M. Campo Susienko
- H. Franklin Taylor, III
- Remo Joseph Tersolo
- Joyce “Jo” Thompson
- Jeannette Toth
- Dennis Alvin Totty
- Dawn A. Van Tuyl
- Carol A. Usher
- Paul Valenzuela
- Ron Vanskiwe
- Calvin A. Vavroucek
- Rita V. Voit
- John Roy Wagnes
- Ives J. Wahrman
- Esther Keleman Walsh
- Jim L. Warren
- Rebecca “Bec” D. Wentworth
- Gertrude “Trudy” Wetterling
- Gwendolyn Whitehead
- Marc L. Wiener
- Dillon Claude Williams
- Robert “Bob” Arthur Williams, II
- Neal Wingfield
- Richard Winterton
- Aaron Wisthnevsky
- Bernard Wohltsetter
- Sheila Carol Wolfson
- Janis Wyman
- Andrew Zalog
- Jennifer Ziegelboim

Honor or memorialize your loved one at: www.mds.foundation.org/donate or contact us at 800-MDS-0839 (within US), 609-298-1035 (Outside US).
LIVING ENDOWMENT DONATIONS HAVE BEEN MADE IN HONOR OF:

Wyn Aubrey-Child  
Submitted by: Donald Child

Bryan Davis  
Submitted by: Joann Davis, Trevor Davis

Barbara Unwin  
Submitted by: Wayne and Lorraine Zerfas

Anandiben Shah  
Submitted by: Janet Kelske

Joan Karlin  
Submitted by: Beverly Taylor

George P. Ratte  
Submitted by: Frederick Jaffke

Brian Scott Anderson  
Submitted by: Ray and Wendy Tarantola  
Arthur Jacobson

Theresa Tintor  
Submitted by: Rhonda Chapman  
Toni Spena, Ryan Goldstein

Rob Allred  
Submitted by: Matthew and Alison French

Ashley Cámara  
Submitted by: Herman B. Lustigman  
Charitable Foundation

James Gisondi  
Submitted by: Kathryn Gisondi

Jill Whitney  
Submitted by: Jan Brown

Jody Senna  
Submitted by: Sher Pollard

Carolyn Wing  
Submitted by: Suzanne Brown

Judith Knapp  
Submitted by: James Snyder

Dorothy Acalin  
Submitted by: Andrea Alexander

Richard Clark  
Submitted by: Amy Clark

Joe Senna, Jr.  
Submitted by: DeRon Senna

William Painter  
Submitted by: Laura Wilson, Carole Flores

Bill Williamson  
Submitted by: Marilyn Williamson

Cherie Willerscheidt  
Submitted by: Jeanne Mandel

Julia McGuire  
Submitted by: Marguerite McKenna

William H. Sargent  
Submitted by: Katharine Sargent

Syd Schneider  
Submitted by: Tanya and Albert Lampert

Mona Kelly  
Submitted by: Ultimate Software Group, Inc.

Frieda "Fritzi"  
Submitted by: Stan and Suzanne Dorf

Opal Belisle  
Submitted by: Randall and Susan Peterson

Jason Curtis  
Submitted by: Charlotte and George Lucas

Did You Know?

The Myelodysplastic Syndromes (MDS) Foundation, Inc. was established by an international group of physicians and researchers to provide an ongoing exchange of information relating to MDS.

Until the Foundation was set up, no formal working group had been devoted to MDS. Since its inception, we have conducted 15 international symposia in Austria, England, the United States (Chicago, Washington, DC), Spain (Barcelona, Valencia), Czech Republic, Sweden, France, Japan, Italy, Greece, Scotland, Germany, and Denmark. The 16th International Symposium will be held in Toronto, Canada on May 5-8, 2021.

A major MDS Foundation effort is our international information network. This network provides patients with referrals to Centers of Excellence, contact names for available clinical trials, sharing of new research and treatment options between physicians, and extension of educational support to physicians, nurses, pharmacists and patients.

In response to the needs expressed by patients, families, and healthcare professionals, we have established patient advocacy groups, research funding, and professional educational initiatives.

The MDS Foundation is a publicly supported organization, exempt from federal income tax under section 501(C)(3) of the IRS code.

Learn more about
The Myelodysplastic Syndromes Foundation, Inc.  
and find additional resources here:
www.mds-foundation.org
At Celgene Patient Support®, we care about making sure you get the help you need to start your prescribed Celgene medicine.

Our Specialists are ready to help you and your family with:

- Understanding your insurance plan
- Learning about financial assistance
- Obtaining information about organizations that may assist you with travel costs to and from your doctor’s office

Enrollment in Celgene Patient Support® is simple—choose the option that is best for you.

- **Enroll online at**
  www.celgenepatientsupport.com

- **Call us at** 1-800-931-8691,
  Monday – Thursday, 8 AM – 7 PM ET,
  and Friday, 8 AM – 6 PM ET
  (translation services available)

- **E-mail us at**
  patientsupport@celgene.com

**Leah**

Celgene Patient Support® Specialist
If you’ve been diagnosed with myelodysplastic syndromes (MDS) with anemia, the phase 3 COMMANDS Trial is a clinical research study investigating a potential treatment option that may help reduce the number of blood cell transfusions you need. To learn more, talk to your doctor and visit ClinicalTrialCOMMANDS.com.
PEVONEDISTAT-3001 (NCT 03268954): Designed to evaluate the safety and efficacy of pevonedistat plus azacitidine versus single-agent azacitidine as a first-line treatment for patients with higher-risk myelodysplastic syndromes (HR MDS), chronic myelomonocytic leukemia (CMML), or low-blast acute myelogenous leukemia (AML).

**Primary endpoint:** Event-free survival (EFS)

**Key secondary endpoint:** Overall survival (OS)

Not a complete list of endpoints.

**Enrolling countries**
Australia, Belgium, Brazil, Canada, Czech Republic, France, Germany, Greece, Israel, Italy, Japan, Mexico, Poland, Russian Federation, South Korea, Spain, Turkey, UK, USA

For more information, including all inclusion and exclusion criteria:
1-844-ONC-TKDA (1-844-662-8532) (US callers)
+1-510-740-1273 (ex-US callers)

www.clinicaltrials.gov or www.takedaoncology.com

For information on enrolling a patient, please contact GlobalOncologyMedInfo@takeda.com.

Pevonedistat is an investigational drug. Efficacy and safety have not been established.
ADVANCING RESEARCH & PATIENT CARE

THE 16TH INTERNATIONAL CONGRESS ON
MYELODYSPLASTIC SYNDROMES

2021
5 - 8 MAY

TORONTO, CANADA

WWW.KENES.COM/MDS